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An overview of the role of Cytochrome P450 enzyme system 




Cytochrome P450 enzymes (CYP) are hemoproteins belonging to the group of 
monooxygenases and one of the main enzymatic systems responsible for drug metabolism. 
In the present study, in vitro approach was applied to evaluate the relation of CYP-catalyzed 
activities between human, rabbit, minipig and mouse, using single substrate assays 
(MultiCYP 7-ethoxycoumarin 0-deethylase (ECOD), CYP1A1/2 7-ethoxyresorufin 0-
deethylase (EROD), CYP2A6 coumarin 7-hydroxylase (COH), CYP3A4 midazolam 1-
hydroxylase (OH-MDZ), and CYP2E1 chlorzoxazone 6-hydroxylase (OH-CLZ)). It was also 
studied plant extracts (Pinus sylvestris, Angelica archangelica, Mentha sp., Citrus grandis) 
and phytochemicals (8-Hydroxybergapten, 5,6-dihydroxyangelicin, α, β-Thujone, α-Thujone, 
angelicin, bergamottin, bergapten, bergaptol, cnidilin, imperatorin, isobergapten, 
isopimpinellin, lanatin, phellopterin, psoralen, sphondin, xanthotoxin) as potential inhibitors 
in CYP-related activities of hepatic human microsomes (CYP1A1/2 (EROD), CYP2A6 
(COH), CYP3A4 (OH-MDZ)). 
This study showed that the lowest ECOD activity was detected in humans and there was no 
similarity between other species. CYP1A1/2 showed equivalent activities. The highest CYP 
activities in humans were found for CYP2A6 and CYP3A4. In CYP2E1 activity, two similar 
groups were recognized: human and mouse versus rabbit and minipig. 
EROD reaction was the most inhibited CYP-mediated reaction. COH reaction was inhibited 
by few compounds. The highest inhibition was detected among angular furocoumarins. Linear 
furocoumarins group had the lower inhibitory concentration of CYP3A4. Thujone showed 
weak inhibition of CYP activities. 
 
Keywords: drug metabolism, food-drug interactions, microsomal enzymatic activities, CYP 
inhibitors, plant extracts and phytochemicals. 
      iii 
 
Abordagem geral sobre o papel do sistema enzimático Citocromo P450 em interacções 




As enzimas do sistema citocromo P450 (CYP) são hemoproteinas pertencentes ao grupo das 
monoxigenases e um dos principais sistemas enzimáticos responsáveis pela metabolização de 
fármacos. 
Neste estudo foi avaliada a relação da actividade catalítica de diferentes CYPs entre humanos, 
coelhos, minipig e murganhos, recorrendo a substratos como sondas individuais in vitro para 
mensurar reacções especificas (MultiCYP 7-etoxicumarina 0-deetilase (ECOD), CYP1A1/2 
7-etoxiresorufina 0-deetilase (EROD), CYP2A6 cumarina 7-hidroxilase (COH), CYP3A4 
midazolam 1-hidroxilase (OH-MDZ), e CYP2E1 clorozoxazona 6-hidroxilase (OH-CLZ)). 
Também foram estudados extractos de plantas (Pinus sylvestris, Angelica archangelica, 
Mentha sp., Citrus grandis) e fitoquímicos (8-hidroxibergaptem, 5,6-dihidroxiangelicina, α, 
β-tujona, α-tujona, angelicina, bergamottin, bergapteno, bergaptol, cnidilina, imperatorina, 
isobergapteno, isopimpinelina, lanatin, felopterina, psoraleno, sphondin, xantotoxina) como 
potenciais inibidores da actividade catalítica dos CYPs microssomais hepáticos humanos 
(CYP1A1/2 (EROD), CYP2A6 (COH), CYP3A4 (OH-MDZ)). 
Neste estudo não foram detectadas actividades similires entre espécies na reacção ECOD e a 
actividade mais baixa foi detectada nos humanos. A reacção EROD dos CYP1A1/2 
demonstrou actividades similares entre as diferentes espécies. As maiores actividades 
cataliticas verificadas nos humanos correspondem aos CYP2A6 e CYP3A4. No estudo da 
reacção do CYP2E1 foram determinados dois grupos distintos com actividades cataliticas 
similares: 1) humanos e murganhos, 2) coelhos e minipigs. 
No estudo de potenciais inibidores dos CYPs, a reacção EROD foi a mais inibida. Pelo 
contrário, a reacção COH foi inibida por poucos compostos. A maioria das inibições ocorreu 
por exposição a furocumarinas angulares. O grupo de furocumarinas lineares teve a menor 
concentração inibitória da reacção OH-MDZ do CYP3A4. Os fitoquímicos α, β-tujona e α-
tujona demonstraram ter um fraco poder inibitório na actividade dos CYPs analisados. 
 
Palavras-chave: Metabolismo farmacológico, interacções farmaco-alimento, actividades 
enzimáticas microsomais, inibidores dos CYPs, extractos vegetais e fitoquimicos. 
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This work was carried out as part of the project “Food-drug interactions: exploring and pre-
empting intricate health risks”, at the Department of Pharmacology and Toxicology, Institute 
of Biomedicine, University of Oulu, lead by Professor Olavi Pelkonen, head of the 
Department. 
Olavi Pelkonen’s research group develops generic in vitro, in vivo and in silico approaches to 
investigate metabolic fate and interactions of any chemicals, be they pharmaceuticals, 
nutritional components, carcinogens or others. Predictions to the in vivo situation are 
performed with the aid of modeling and simulation tools and targeted in-depth studies are 
undertaken for the confirmation of predictions. 
The major goal of this project is to characterize the risks and reduce future cases of harmful 
food-drug interactions, particularly among the more sensitive sections of the population like 
the elderly and patients undergoing extensive drug treatments due to severe diseases. The 
specific objectives of the proposed research are: 
1. Survey and selection of individual compounds and/or compound groups in selected local 
food sources (e.g. fruits, vegetables, berries, and beverages, as well as commonly used 
spices); 
2. Studying the effects of the different compounds from the food extracts and similar sources 
on the activity of human cytochrome P450 monooxygenases (CYPs) and human UDP-
glucuronosyltransferases (UGTs); 
3. Assessing the effect of the different compounds on the expression level of major human 
CYPs and UGTs; 
4. Analyzing the metabolism of phenolics compounds, such as flavonoids and coumarins, 
from fractionated food extracts by the different human CYPs and UGTs. 
This thesis is based in two different studies. The first study was an independent project meant 
to compare CYP-catalyzed activities between different species, which led to the presentation 
of a communication to the 11th International Congress of the European Association of 
Veterinary Pharmacology and Toxicology (see annex I). The second study was part of the 
main project already described, which consisted in the analysis of plant extracts and 
phytochemicals as possible CYP inhibitors, using single substrate assays in vitro.  
 




In the modern world, man and other animals have been progressively more exposed to a huge 
diversity of chemical compounds, foreign to their normal composition and potentially toxic, 
known as xenobiotics. These compounds cover a wide range of drugs, pesticides, food 
additives and pollutants that can be available in the environment, food or part of medical 
treatments. 
Animals possess several defense mechanisms able to act as barriers against the entry of 
chemical compounds or to eliminate them after being exposed. These mechanisms can be 
classified as mechanical, cellular or enzymatic systems. 
After coming in contact with organisms, most of the foreign compounds undergo a number of 
chemical reactions performed by hepatic and extra-hepatic enzyme systems, known as 
metabolism. In case of drugs, the metabolism rate affects directly its bioavailability, the 
pharmacological effect, therapeutic response and most of the pharmacokinetic properties. 
Most of the tissues and organs are well equipped with diverse and various drug metabolizing 
enzymes (DMEs), including phase I, phase II metabolizing enzymes, as well as phase III 
transporters. The later is characterized by transmembrane transporters that facilitate 
movement of drugs/metabolites across cellular membranes before and after phase I and/or 
phase II. So, the enzymatic pathways involved in metabolism can be classified in two main 
enzymatic systems: 1) Phase I enzymes catalyze functionalization reactions and are mainly 
constituted by Cytochrome P450 enzyme system (CYP); 2) Phase II enzymes involve 
conjugative reactions, mostly by UDP-glucuronosyltransferases and glutathione S-
transferases, responsible for increase the hydrophilicity of the parent compound after phase I. 
Usually, metabolism yield more polar derivatives (metabolites) which may leave the body via 
the urinary and biliary routes or be excreted by perspiration, tears, saliva, gastric juice, semen, 
milk or eggs. However in some cases, metabolism can be harmful to the body by leading to 
metabolic activation or by interference of drug interactions. The former involves the 
formation of reactive forms from inactive parent compounds that may lead to bioavailability 
problems, interindividual variation, metabolic interactions and idiosyncrasies. Drug 
interaction is a situation in which the activity of a drug is affected by another drug or a food 
component, in most of the cases by changing drug metabolism. One notable system involved 
in metabolic drug interactions is Cytochrome P450 enzyme system. This system may be 
affected by either enzymatic induction or inhibition. 
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So, the absence of detailed information regarding drug metabolism and drug interactions can 
result in adverse effects, therapeutic failure or toxicity from unanticipated overdose or 
metabolic reactions. 
During the past decades, in human pharmacology and toxicology great emphasis have been 
placed upon a detailed knowledge of DMEs in laboratory animals and man. In contrast, 
knowledge of biotransformation enzymes and their variability in veterinary species, which 
include companion and farm animals, is still rather insufficient. 
Nowadays, the importance of research on drug metabolism in veterinary species is growing, 
especially regarding the importance of companion animals in western countries. Because 
several therapeutic areas require long-term pharmaceutical intervention on the time scale of 
months or years (e.g. infectious disease including parasitism, pain and inflammation, cancer, 
behavior, cardiovascular, and endocrinology disorders), prolonged exposure and accumulation 
of drugs may increase the risk of drug-drug interactions. Also, the growing market for pet 
medicines devoted to improving quality of life rather than treating a specific disease is 
expected to increase the number of pets receiving pharmaceutical agents or a regular basis. 
The importance of drug metabolism is also growing in farm animals, not only because of 
permanent exposure to industrial or agricultural contaminants, but also because of the 
frequent use of pharmacologically active substances. So, the relevance of metabolism in these 
species also concerns public health. For better understanding, in next chapters will be 
discussed the importance of pharmacokinetic, liver and DMEs in drug metabolism, and some 
data concerning CYPs and drug interactions.  
The present thesis was aimed to: 
1. Explore the available data on CYP regulation, expression, substrate specificity and 
potential interactions in animal species and in human medicine, illustrating the main 
role performed by CYP system in drug development, clinical treatments, food 
management and animal production. 
2. Find similarities between CYP-related activities in humans and three different 
laboratory animal species (rabbit, minipig and mouse). According to the final results, 
it may help to identify possible extrapolations between species and to find a suitable 
animal model for human CYP-mediated metabolism. 
3. Identify potential human CYP inhibitors among several plant extracts, including 
purified herbal compounds. This subject concerns public health and food safety, which 
can lead to harmful food-drug interactions in humans and, it may also affect, animal 
species. 
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1. Review of the literature 
 
1.1. Pharmacology as a science 
 
Pharmacology is the science field responsible for the study of drugs. The pharmacology field 
encompasses the drug’s history, origin, composition and physicochemical properties, 
interactions, toxicology, therapeutic applications and mechanisms involved in their actions, 
such as absorption, distribution, biotransformation and excretion. All of these fields can be 
comprised in several subdisciplines or branches (Dimasi, Caglarcan, & Wood-Armany, 2001; 
Guimarães, Moura, & Silva, 2006; Roots et al., 2004; Scatena, Bottoni, Botta, Martorana, & 
Giardina, 2007; Spinosa, Gorniak, & Bernardi, 2006): 
- Pharmacodynamics (study of the manner in which drugs act on the body and their 
mechanisms and effects); 
- Pharmacokinetics (study how the body affects drugs after administration and 
interactions of medications within the body); 
- Pharmacognosy (study of the characteristics and uses of drugs); 
- Pharmacy (science of preparing and dispensing medications); 
- Pharmacotoxicology (study the toxic effect of xenobiotics, which also includes drugs, 
in living organisms); 
- Pharmacogenetics (study or clinical testing of genetic variation that gives rise to 
differing response to drugs); 
- Pharmacogenomics (application of genomic technologies to new drug discovery and 
further characterization of older drugs);  
- Pharmaeconomics (compares the value of one pharmaceutical drug or drug therapy to 
another, evaluating the cost versus effects). 
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1.2. Pharmacokinetics and Toxicokinetics 
 
During the biological disposition of a drug or other xenobiotic, in the pharmacokinetic or 
toxicokinetic phase respectively, there are four distinct processes which include the extent and 
rate of absorption, distribution, metabolism and excretion. This is commonly known by the 
acronym ADME (see figure 1). Nevertheless, in toxicokinetics is possible to use the acronym 
ADME-Tox or ADMET when the potential or real toxicity of the compound is taken into 
account (Ionescu & Caira, 2005; Lin et al., 2003). 
 
Figure 1. Schematic representation of the interrelationship of the four main processes - ADME (modified from 
Ionescu & Caira, 2005) 
 
 
On the other hand, it should be noted that depending on their respective pharmacokinetics, a 
given dose of drug may be undergoing more than one of these processes simultaneously, e.g. 
metabolism of absorbed drug may commence while part of the administered dose is still being 
absorbed; or it can over lap metabolism being directly excreted (Guimarães, Moura, & Silva, 
2006; Ionescu & Caira, 2005) 
Despite the fact that ADME scheme is the most consensual, some authors include also the 
term liberation. This process is characterized by the dissolution rate of the drug from the solid 
particles, where the surface phenomena at the solid/ liquid interface play an important part in 
drug delivery. Therefore, pharmacokinetics can be also referred to as the LADME concept 








Drugs and other xenobiotics can be introduced into the body by a wide variety of routes of 
administration. The most important administration routes are listed in table 1. 
  
Table 1. Routes of administration of drugs (modified from Ahokas & Pelkonen, 2007) 
Parenteral routes 
Enteric routes 












After the drug being intake, in case of enteric routes and some parenteral routes (e.g. nasal), 
the pharmacologically active compound only produces effect if its site of action is reached. 
Therefore it needs to transpose biological membranes, undergoing in a process of movement 
from the site of application into the extracellular compartment of the body. Then it needs to be 
present in appropriate concentrations at its sites of action and remains there for an adequate 
period of time before being excreted. The main physiologic mechanisms of crossing 
membranes are filtration (through the small pores in the membranes), passive diffusion, 
facilitated diffusion, active transport and pinocytosis (Ahokas & Pelkonen, 2007; Guimarães 
et al., 2006). 
Thus, absorption can be defined as the sum of all processes that a compound may undergo 
after its administration before reaching the systemic circulation. Therefore, the blood 
concentration of active drug attained depends primarily upon the extent and rate of 
absorption. Although intravenous administration is an exception, since the drug is introduced 
directly in the bloodstream, there is no absorption (Ionescu & Caira, 2005; Spinosa et al., 
2006).  
Besides the physicochemical properties of the drug molecules (e.g. lipophilicity and 
ionization) and membranes involved in absorption, there are other limiter factors such as the 
irrigation intensity and thickness of the membrane, the area, time and way of contact between 
the drug and membrane (Spinosa et al., 2006). 




After the drug’s administration, it distributes from the absorption place throughout the body 
via bloodstream. This process can be described as a combination of reversal transference of 
drug molecules from the systemic circulation to extravascular space, and interactions with 
macromolecules present in various body fluids and tissues. 
The rate and extent of the drug’s distribution is directly influenced by interactions of the drug 
with body components, which depends on both the physicochemical properties of the drug in 
question (e.g. lipid solubility, ionization degree, pKa, molecular weight) and physiological 
parameters (e.g. pH, extent of plasma protein binding, permeability of membranes, blood 
flow, nature of the tissue) (Ahokas & Pelkonen, 2007; Gibson & Skett, 2001; Ionescu & 
Caira, 2005). Based on those determining factor, the main mechanisms involved in drug’s 
distribution are summarized below (Ionescu & Caira, 2005; Uetrecht & Trager, 2007):  
• Passive diffusion across lipid membranes is the main process by which most drugs 
across cell membranes. In this case, drug molecules move from a high to a low 
concentration area; 
• Hydrostatic pressure represents a pressure gradient between the arterial end of the 
capillaries entering the tissue and the venous capillaries leaving the tissue; 
• Presence of carrier-mediated active transport processes involving the xenobiotic. In 
this process, substances are moved across a cell membrane from a low to a high 
concentration region; 
• Drug binding to plasma proteins (e.g. albumin, glycoproteins and hormonal 
transporters), blood cells (e.g. erythrocytes), lipids and various tissue proteins is very 
important in drug distribution. The fraction of the bound drug can be as high as > 90% 
or as low as < 20%. Drug-protein binding is influenced by several factors, such as 
drug concentrations and lipophilicity. Generally, the higher is the lipophilicity of a 
drug, the stronger is the binding to tissue protein and the greater its distribution 
(higher ability to cross the cell membrane). So, the bioavailability of the drug to pass 






      8 
 
1.2.3. Drug Elimination  
 
As previously referred, animals have several defense mechanisms to eliminate foreign 
compounds, such as mechanical, cellular and enzymatic systems. Biotransformation is one of 
these defense mechanisms, where compounds (e.g. nutrients, amino acids, toxins, or drugs) 
undergo chemical changes for further elimination (Ionescu & Caira, 2005). 
After being absorbed by the organism, drugs can be directly eliminated unmodified when 
soluble, via the urinary and biliary routes, or other excreta (generally in minor amounts). 
However, in most of the cases, it is necessary the conversion of drugs in more polar 
compounds (soluble), which undergo a number of chemical reactions known as drug 
metabolism (an example of biotransformation). In this process, parent drug is biotransformed 
into metabolites, being excreted then mainly by urine or/and bile ( 
figure 2). Thus, the elimination (or clearance) of a drug refers to the sum of all clearance 
processes by all contributing organs, that remove or contributes to the removal of drugs or 
other foreign agents from the body. These include excretion and metabolism (Ahokas & 
Pelkonen, 2007; Guimarães et al., 2006). 
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1.2.3.1.  Metabolism 
 
The main goal of drug metabolism, as mentioned before, is to allow the excretion of non-polar 
or too lipophilic compounds from the body by changing their chemical structure (which 
includes active part of medications) making them more water-soluble and more readily 
excreted mainly by the kidney. The enzymatic systems involved in the drug’s 
biotransformation are known as drug metabolizing enzymes (DMEs), being responsible for 
the drug’s chemical conversion in metabolites. Paradoxically, DMEs can also metabolically 
activate biological inert compounds (bioactivation) to electrophilic derivates that can cause 
toxicity or even carcinogenesis (Gonzalez, 2005; Uetrecht & Trager, 2007). 
Most of the tissues and organs, such as liver, lung, kidney, intestine and rumen (in case of 
ruminants) are well equipped with diverse and various DMEs (phase I, phase II metabolizing 
enzymes), as well as phase III transporters, which are present in abundance either at the basal 
non-stimulated level, and/or are inducible at elevated level after exposure to xenobiotics. 
However, these enzymes are mostly located in liver, which will be described in a later section 
(Fu, Xia, Lin, & Chou, 2004; Josephy, Guengerich, & Miners, 2005; Turpeinen, 2006). 
DMEs are divided in two main enzymatic systems, according to their function and chemical 
reactions (Ionescu & Caira, 2005; Szakács, Váradi, Özvegy-Laczka, & Sarkadi, 2008; Xu, Li, 
& Kong, 2005): 
• The phase I enzymes catalyze functionalization reactions (see table 2), which 
introduce a polar functional group to a parent molecule to form a metabolite. 
• The phase II enzymes catalyze conjugation reactions, which conjugate a polar moiety 
to the parent compound or its phase I metabolite (see table 2). Therefore, the 
metabolites resulting from phase II are usually more polar than the parent molecule.  
 
Table 2. Reactions of phase I and phase II (modified from Gibson & Skett, 2001) 
Phase I Phase II 




Isomerisation Amino acid conjugation 
Miscellaneous Glutathione conjugation 
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Finally, phase III is constituted by transmembrane transporters, such as P-glycoprotein (P-gp), 
multidrug resistance-associated protein (MRP), organic anion transporting polypeptide 2 
(OATP2), that facilitate movement of drugs/metabolites across cellular membranes after and 
before phase I and/or phase II. So, these transmembrane transporters are not only related with 
drug metabolism, but also provide a barrier against drug penetration, and play crucial roles in 
drug absorption, distribution and excretion (Xu et al., 2005). 
 
 
1.2.3.2.  Excretion 
 
Excretion is the final step in the xenobiotic elimination. Nonetheless, as already mentioned 
before according to the xenobiotic properties it may be excreted directly unchanged or it may 
previously require being biotransformed. 
The most important organ of excretion is the kidney, although some substances can be 
excreted in the expired air (through the lungs), bile, perspiration, tears, saliva, gastric juice, 
semen, milk or eggs (Lin et al., 2003; Spinosa et al., 2006; Szakács et al., 2008). Most of 
these drugs are excreted rather by these alternative routes owing to be more lipophilic. 
Below is summarized the most important excretion routes:  
• Renal excretion takes place mainly by glomerular filtration; however as the glomerular 
filtrate passes through the proximal tubule, some solute may be reabsorbed (tubular 
reabsorption) through the tubular epithelium and returned to the blood. Drugs also 
may be reabsorbed in the distal tubule, in which case the pH of the urine is extremely 
important in determining the reabsorption rate (in accord with the principle of non-
ionic diffusion and pH partition). It should be take in consideration that the urinary 
pH, and hence drug excretion, may fluctuate widely depending on the diet, exercise 
level, drugs, day time and other factors (Guimarães et al., 2006; Ionescu & Caira, 
2005). 
• Biliary excretion and fecal elimination include xenobiotics that are secreted into the 
bile usually pass into the intestine; from here, they may be reabsorbed and integrate 
the enterohepatic circulation (this system provides a reservoir for the drug). If a drug is 
not absorbed completely from the intestine, the unabsorbed fraction will be eliminated 
in faeces (Guimarães et al., 2006; Ionescu & Caira, 2005). 
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• Alveolar excretion is another example of an alternative route of excretion, in which 
due to the large alveolar area and high blood flow at this level, it makes lungs ideal for 




1.3. The role of liver in drug metabolism 
 
In drug metabolism, most of pharmacokinetic differences between and within species have it 
major determinant in chemical processes variability. The latter is mainly due to DMEs, which 
most of organs possess a wide range. Thus, DMEs plays a central role in pharmacokinetic, 
especially in the elimination phase (Hewitt et al., 2007). 
In this way, liver represents one of the main organs in drug metabolism by his anatomic and 
histological singularity, cell specialization and by possessing the highest amount of DMEs. 
The previous feature is attributable to the combination of two characteristics - high 
concentration of DMEs in hepatocytes and the liver size (Spinosa et al., 2006). 
 
 
1.3.1. Hepatic clearance 
 
One of the liver’s functions is to use biotransforming enzymes to convert lipophilic agents in 
water-soluble enough to be cleared by the kidney. So, it must extract the drug from the 
circulation, biotransform (metabolize) it and then return the metabolite to the blood. The liver 
can also active clear or physically remove its metabolic products by excreting them in the 
bile, as already explained (Coleman, 2006). 
The liver’s capability to remove a specific compound from circulation (hepatic clearance) is 
mainly conditioned by his blood flow and the intrinsic hepatic clearance. The latter is 
determined by the excretory capacity, enzymatic activity and affinity. Nonetheless, these 
physiologic variables rely on interspecies differences and can be influenced by drug therapies, 
xenobiotics interactions, hepatic pathologies, as well in other organic systems (e.g. chronic 
kidney disease and congested heart failure) (Braz, 2005). 
The hepatic biotransformation can intervene in two different stages of the drug’s life, in a 
later stage during the distribution or immediately after the absorption owing to the anatomic 
position of the liver, which is interposed between the gastrointestinal tract and systemic 
circulation (Braz, 2005). 
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All drugs absorbed from the small intestine are transferred to the liver by portal circulation. 
To be absorbed from the intestine, before entering the hepatic portal circulation, the drug must 
pass through the intestine wall, where it can be pumped back out of the gut wall into the 
lumen by the efflux proteins and metabolized by various enzymes in the intestine wall cells. 
When the drug achieves the liver by the hepatic portal circulation, it may partially 
metabolized before entering the systemic circulation, whereby their concentration can be 
reduced before reach the site of action (see figure 3). This phenomenon is called first pass 
metabolism. Drugs having a high first pass rate (or poor absorption) are referred to have a low 
bioavailability (Braz, 2005; Coleman, 2006; Gibson & Skett, 2001). 
 














In some drugs, most part of the administrated dose is lost before it reaches the systemic 
circulation. Thus, if the given dose and the amount that actually reaches the plasma are 
known, it is possible to know how much enters the system. This is known as the 
bioavailability (F) of the drug and it is calculated by the equation 1. For this reason, 
theoretically, drugs administered intravenously have a bioavailability of 100% (Ahokas & 
Pelkonen, 2007; Braz, 2005; Coleman, 2006). 
 
















- xAUC →0 : Area under the plasma concentration versus 
time curve from time 0 to time x  after intravenous 
dosage (IV) / oral administration (oral). 
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1.3.2. Liver cells 
 
The liver is composed of both parenchymal and nonparenchymal cells (Junqueira & Carneiro, 
2005; Kuntz, 2006). 
The nonparenchymal cells include: 
• Endothelial cells: They delineate the sinusoidal spaces, allowing exchanges between 
blood and hepatocytes. These cells also produce prostaglandins, endothelins, nitric 
oxide and some extracellular components (Braz, 2005)  
• Kupffer cells: These cells are stationary macrophages responsibles for immune 
surveillance and release inflammatory mediators (Kuntz, 2006). 
• Ito cells: They are also known as lipocytes, fat storing cells or stellate cells, and serve 
to store vitamin A and lipids, but upon liver injury they can differentiate into 
fibroblasts, being able of producing collagen. These cells only represent 5-8% off all 
liver cells and they are located in space of Disse (or perisinusoidal space, which is 
located between a hepatocyte and a sinusoid) (Junqueira & Carneiro, 2005; Kuntz, 
2006). 
The parenchymal cells, commonly known as hepatocytes, constitute approximately 60% of all 
liver cells and 80% of the liver weight. They are also the main responsible for most of the 
liver’s functions, being able of synthesizing blood components (e.g. serum albumin, 
fibrinogen, clotting factors), cholesterol, bile salts, phospholipids and their own structural 
proteins and intracellular enzymes. So, hepatocytes are provided with numerous 
mitochondria, and large amounts of rough and smooth endoplasmic reticulum, which are 
necessary to synthesize and secrete proteins. Regarding their unique metabolic characteristics 
and possessing all DMEs in liver, these cells are the major site of xenobiotics 
biotransformation (Junqueira & Carneiro, 2005; Kuntz, 2006). 
 
 
1.3.3. Biotransforming enzymes of liver 
 
The DMEs constitutes the group of biotransforming enzymes, and as already referred, those 
are mostly located in the liver - more precisely in hepatocytes (Wexler & Anderson, 2005). 
Phase I and II are the two main enzymatic systems that compose DMEs and the only enzymes 
truly responsible for biotransformation itself. So, both phases will be discussed in more detail 
in following topics (Ionescu & Caira, 2005). 
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1.3.3.1. Phase I Enzymes and Reactions (Functionalization Reactions) 
 
The main function of phase I is to prepare the compound for phase II and not to prepare the 
drug for excretion. So, phase I enzymes catalyzes functionalization reactions, by adding or 
uncovering functional groups on xenobiotics with increasing polarity or hydrophilicity 
creating a suitable substrate for Phase II metabolism (see figure 4) (Gibson & Skett, 2001). 
Phase I metabolism includes oxidation, reduction, hydrolysis and hydration reactions, as well 
as other rarer miscellaneous reactions (see table 2) (Ahokas & Pelkonen, 2007; Josephy et al., 
2005). 
 






Oxidation involves the enzymatic addition of oxygen, removal of hydrogen or changing the 
oxidative state of the xenobiotic. These reactions are mainly catalyzed by CYPs, but other 
enzyme groups can be also involved (Olavi Pelkonen et al., 2008; Xu et al., 2005). 
 
a. Oxidations involving CYPs (the microsomal mixed-function oxidase): 
Oxidations performed by the microsomal mixed-function oxidase (MFO) system are 
considered separately, because of its major role and the diversity of reactions performed by 
this enzyme system (Gibson & Skett, 2001; Uetrecht & Trager, 2007). 
The mixed-function oxidase system found in microsomes (small vesicle that is derived from 
fragmented smooth endoplasmic reticulum produced when tissues, such as liver, are 
homogenized) of many cells (mainly in liver, but also in kidney, lung and intestine) performs 
many different functionalization reactions (summarized in table 3) (Braz, 2005; Gibson & 
Skett, 2001). 
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All of these reactions require the presence of molecular oxygen and NADPH as well as the 
complete mixed-function oxidase system (cytochrome P450, NADPH-cytochrome P450 
reductase and lipid) (Gibson & Skett, 2001). All reactions involve the initial insertion of a 
single oxygen atom into the drug molecule. A subsequent rearrangement and/or 
decomposition of this product may occur, leading to the final product (Uetrecht & Trager, 
2007). 
 
Table 3. Reactions performed by the microsomal mixed-function oxidase system (Ionescu & Caira, 2005) 
Reaction Substrate 
Aromatic hydroxylation Lidocaine 





Oxidative deamination Amphetamine 
N-Oxidation 3-Methylpyridine 
S-Oxidation Chlorpromazine 
Phosphothionate oxidation Parathion 
Dehalogenation Halothane 
Alcohol oxidation Ethanol 
 
This enzymatic system is involved in both xenobiotics (drugs) and endogenous metabolism. 
The latter applies to the metabolism of steroid hormones, thyroid hormones, fatty acids, 
prostaglandins and derivates. Steroid biosynthesis is dependent on CYPs at many stages, 
where the rate-limiting step is the conversion of cholesterol to pregnenolone (see figure 5). 
Pregnenolone is the prohormone involved in the steroidogenesis of progesterone, 
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b. Oxidations not catalyzed by CYPs: 
Some other enzymes in the body not related to CYPs can oxidize drugs. They are listed in 
table 4. Most of these enzymes are primarily involved in endogenous compound metabolism 
(Ionescu & Caira, 2005; Nebbia, 2001).  
 
Table 4. Other oxidative enzymes  
Flavin-containing monooxygenase system Co-oxidation by peroxidases 
Alcohol dehydrogenase Amine oxidases 
Aldehyde dehydrogenase Aromatases 
Xanthine oxidase Alkylhydrazine oxidase 
 
 
1.3.3.1.2. Reductive metabolism 
 
Reductive reactions of certain functional groups are not as common as oxidative and some of 
them can be catalyzed by hepatic microsomal enzymes. These reactions usually require 
NADPH, however they are generally inhibited by oxygen, unlike the mixed-function oxidase 
reactions that use oxygen as a main reagent. A list of the types of compounds undergoing 
reduction is given in table 5 (Gibson & Skett, 2001; Nebbia, 2001). 
 
Table 5. Compounds undergoing reduction by hepatic microsomes  
Azo-compounds N- and S-Oxides 
Nitro-compounds Disulfides 
Epoxides Alkenes 
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Azo- and nitro-reduction can be catalyzed by CYPs, but also by NADPH-CYP reductase, and 
can involve substrates such as chloramphenicol and prontosil red (forming sulfanilamide), 






Hydrolysis reactions can be performed by several enzymes that readily catalyzed esters, 
amides, hydrazides and carbamates (Abass et al., 2009; Ionescu & Caira, 2005). 
• Ester hydrolysis is performed in plasma by non-specific acetylcholinesterases, 
pseudocholinesterases and other esterases or it can occur in liver by specific esterases 
for particular groups of compounds. 
• Amides can be hydrolyzed by the plasma esterases (non-specific), but they are more 
likely to be hydrolyzed by the liver amidases. 






This reaction can be considered as a specialized form of hydrolysis, where a molecule of 
water is added to the compound structure without leading to the compound dissociation. 
Hydration can be carried out by many enzymes, such as epoxide hydrolase hydrates (also 
known as Epoxide hydratase). This enzyme is present in large quantity in endoplasmic 
reticulum and converts epoxides from the degradation of aromatic compounds to trans-
dihydrodiols which can be conjugated (see figure 6) and excreted from the body (Abass et al., 
2009; Gibson & Skett, 2001; Uetrecht & Trager, 2007). 
 
Figure 6. Hydration of Benxo[a]pyrene-4,5-epoxide (Gibson & Skett, 2001). 
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1.3.3.1.5. Other reactions 
 
There are many other reactions that have been proposed as possible routes of metabolism for 
specific drugs. Some of these reactions are listed in table 6 (Abass et al., 2009; Uetrecht & 
Trager, 2007). 
 
Table 6. Other reactions involved in drug metabolism (Abass et al., 2009) 
Reaction Compound 









1.3.3.2. Phase II Enzymes and Reactions (Conjugation Reactions) 
 
After phase I, products are not usually eliminated, but undergo in conjugation reactions to 
form a highly polar conjugates to turn them more easily excreted. The phase II reactions 
involve a diverse group of enzymes often requiring co-factors or substrate derivates (see table 
7), which must be replenished through dietary sources (Josephy et al., 2005; Xu et al., 2005). 
Glucuronidation, sulfation and glutathione conjugation are the most prevalent reactions of 
phase II metabolism, which may occur directly on the parent compounds or, as normally 
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Table 7. Conjugation reaction (Gibson & Skett, 2001) 





















Amino acid conjugation  -COOH 
Glutathione conjugation Glutathione-S-transferase Epoxide 
Fatty acid conjugation  -OH 





Glucuronidation (conjugation with α-D-glucuronic acid) represents the major route for sugar 
conjugation, although it is also possible to occur with other sugars (glucose, xylose and 
ribose, though less common). This reaction is the most frequent conjugation due to the 
relative abundance of the co-factor (UDP-glucuronic acid) and the ubiquitous nature of the 
enzyme (UDP-glucuronosyltransferase) (Abass et al., 2009; Gibson & Skett, 2001). 
The glucuronidation reaction consists in the transference of the glucuronosyl group from 
uridine 5'-diphospho-glucuronic acid (UDPGA) to the substrate (attached via a glycosidic 
bond), the resulting glucuronide product (also known as glucuronoside) has a much higher 
water solubility than the original substance (Gibson & Skett, 2001). 
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Glucuronide formation is quantitatively the most important form of drugs conjugation 
(alcohols, phenols, amines, thiols, hydrozylamines and carboxylic acids). It is also a common 
pathway of metabolism for many endogenous compounds (steroid hormones, catecholamines, 





Sulfation is a conjugation pathway for many drugs and endogenous compounds, which are 
constituted mainly by phenols, but also alcohols, amines or thiols. This conjugation is 
catalyzed by a sulfotransferase (present mainly in liver) in the presence of the drug or 
endogenous compound and 3’phosphoadenosine-5’phosphosulfate (PAPS) (Mizutani, 2003) . 
Most of the drugs and endogenous compounds metabolized by glucuronidation can also be 
sulfated, leading to the possibility of completion for the substrate between the two pathways. 
In general glucuronide conjugation occurs at higher rate than sulfation, due to the limited 
supply of PAPS in cells when compared with UDPGA levels (Gibson & Skett, 2001; Uetrecht 





These reactions are mainly oriented to endogenous compound metabolism, but some drugs 
can be methylated by non-specific methyltransferases found in lung and by the physiological 
methyltransferases. However, unlike other conjugation reactions, methylation leads to less 
polar products, delaying the excretion of the drug (Abass et al., 2009; Ionescu & Caira, 2005). 
Metals such as mercury can be converted in methyl mercury by this process. The latter is 





Acetylation is performed by N-acetyltransferase, which is mainly located in Kupffer cells (not 
in hepatocytes, the most usual location), although it can also be found in reticuloendothelial 
cells of the spleen, lung and gut. The location of the enzyme may be related to its role in 
leukotriene biosynthesis (Coleman, 2006). 
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Acetylation reactions are involved in aromatic amines and sulfonamides metabolism, which 
require, as a co-factor, acetyl-CoA (Abass et al., 2009). 
 
 
1.3.3.2.5. Amino acid conjugation 
 
This conjugation reaction is a special form of an N-acylation. This reaction involves 
metabolites containing a carboxylic acid and the amino group of amino acids. There are 
several enzymes implicated (cytosolic and mitochondrial) and cofactors (ATP and acetyl-
CoA) that activate the carboxylic acid group and results in the formation of an amide bond 
(Gibson & Skett, 2001; Uetrecht & Trager, 2007). 
 
 
1.3.3.2.6. Glutathione conjugation 
 
Glutathione acts as a protective compound within the body, removing potentially toxic 
electrophilic compounds. Those can be drugs or phase I products. The glutathione conjugates 
may be excreted directly in urine or more usually in bile, but more often continue for other 
conjugation reactions (Gibson & Skett, 2001).  
The enzymes catalyzing these reactions are glutathione-S-transferases, which are located in 
liver, kidney, intestines and other tissues .(Ionescu & Caira, 2005) 
 
 
1.3.3.2.7. Fatty acid conjugation 
 
The fatty acids involved - stearic and palmitic acids - are conjugated to drug by esterification 
reaction, being catalyzed by the microsomal fraction of the liver. Nevertheless, little is known 
about this reaction (Abass et al., 2009; Gibson & Skett, 2001). 
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1.4. Cytochrome P450 (CYP) enzyme system 
 
Cytochrome P450 (CYP) is not a single enzyme, but a numerous family of heme-containing 
(hemoprotein) enzymes with closely related isoforms, belonging to the group of 
monooxygenases. This enzymatic system is found in almost all organisms, being crucial for 
the oxidative, peroxidative, and reductive metabolism of exogenous and endogenous 
compounds (Gibson & Skett, 2001; Turpeinen, 2006).  
In prokaryotes, CYPs usually perform a plastic function, whereas in eukaryotes their 
functions are very diverse. In mammals, are embedded in the membrane of the endoplasmic 
reticulum, working as a terminal oxidase component of an electron transfer system. CYPs are 
involved in biosynthesis and metabolism of many physiologically active substances (steroids, 
fatty acids, eicosanoids, vitamins and bile acids), and act as the major xenobiotic metabolizing 
enzymes (Arpiainen, 2007).  
 
  
1.4.1. Chemical structure 
 
Cytochrome P450 is classified as a hemoprotein constituted approximately by 500 amino 
acids and by an iron protoporphyrin IX as the prosthetic group (non-protein component of a 
conjugated protein) (see figure 7). The monomeric molecular weight is approximately 45.000 
to 55.000 daltons. This prosthetic group is common to other hemoproteins, but with different 
biological functions, such as hemoglobin and myoglobin (Gibson & Skett, 2001; Zuber, 
Anzenbacherová, & Anzenbacher, 2002). 
 
Figure 7. Structure of iron protoporphyrin IX (Gibson & Skett, 2001). 
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Sequence identity among CYPs is often low (approximately 20%) and only have been 
identified three absolutely conserved amino acids. Highest structural conservation is found in 
the core of the protein around the heme and reflects a common mechanism of electron and 
proton transfer and oxygen activation. The most variable regions are associated with either 
amino-terminal anchoring or targeting of membrane-bound proteins, or substrate binding and 
recognition; the latter regions are located near the substrate-access channel and catalytic site 
and are often referred to as substrate-recognition sites. They are described as flexible, moving 
upon binding of substrate so as to favor the catalytic reaction. Other variations reflect 
differences in electron donors, reaction catalyzed or membrane localization (Gibson & Skett, 
2001; Werck-Reichhart & Feyereisen, 2000). 
 
 
Figure 8.  Secondary and tertiary structure of CYP (adapted from Werck-Reichhart & Feyereisen, 2000). 
 
 
The diagram in figure 8 shows the secondary structure and arrangement of a typical CYP. The 
α helices are represented by blue boxes. Groups of cream arrows outlined with dotted lines 
represent β sheets, lines, coils and loops. There are usually around four β sheets and 13 α 
helices defining one domain that is predominantly β sheets and one that is predominantly α 
helices. The first domain is often associated with substrate recognition and the access channel, 
the second with the catalytic center (Werck-Reichhart & Feyereisen, 2000). 
 
 




The most common reaction catalyzed by CYPs is a monooxygenase reaction of lipophilic 
compounds by inserting one atom of molecular oxygen into the parent compound (RH) while 
the other oxygen atom is reduced to water with the help of reducing equivalents from 
NADPH. The previous reaction can be described by the following scheme (Ionescu & Caira, 
2005; Turpeinen, 2006): 
 
RH + NADPH + H+ + O2  ROH + NADP+ + H2O 
 
The attached hydroxyl group is used as a reactive group by other enzymatic systems for 
further modifications. Other reactions catalyzed by CYPs include epoxidations, peroxidations, 
deaminations, desulfurations, dehalogenations and reductive reactions (Turpeinen, 2006). 
CYPs can be divided into four classes depending on how electrons from NAD(P)H are 
delivered to the catalytic site (Werck-Reichhart & Feyereisen, 2000): 
• Class I: CYPs require both an FAD-containing reductase and an iron sulfur ferredoxin; 
• Class II: CYPs require only an FAD/FMN-containing CYP reductase for transfer of 
electrons; 
• Class III: Enzymes are self-sufficient and require no electron donor; 
• Class IV: CYPs receive electrons directly from NAD(P)H. 
 
In the endoplasmic reticulum, electrons are donated to CYPs by FAD/FMN-containing CYP 
reductase (also known as NADPH-cytochrome P450 reductase) (see figure 9). In 
mitochondria, ferredoxin acts as a single electron carrier from NADPH to FAD-containing 
ferredoxin reductase (FR) and CYP enzymes (Anzenbacher & Anzenbacherova, 2001; Gibson 
& Skett, 2001; Turpeinen, 2006). 
 
      25 
 





The name cytochrome P450 (CYP) is derived from the unique optical absorption peak at 
wavelength 450 nm (around 420 nm for the majority of other haemoproteins) in the presence 
of a reducing agent and carbon monoxide (Turpeinen, 2006). 
The first CYP named was CYP1A1 and since his discovery, it has been sequenced more than 
7700 distinct CYP sequences of 700 families. The diversity of CYP enzymes has led to the 
need to classify single CYP forms into families and subfamilies. The nomenclature is based 
on amino-acid identity, gene organization and phylogenetic criteria (Nelson et al., 1996): The 
amino acid sequences of enzymes in the same family are at least 40% identical, while 
members of subfamilies must share more than 55% amino acid identity. The abbreviation 
CYP refers to genes encoding CYP enzymes, and the enzymes themselves, followed by an 
Arabic numeral indicating the gene family, a capital letter indicating the subfamily, and 
another Arabic numeral representing the individual gene within the subfamily. Genes within a 
subfamily are numbered in order of discovery, regardless of species. The convention is to 
italicize the name when referring to the gene. However, some gene or enzyme names for 
CYPs may differ from this nomenclature, denoting the catalytic activity and the name of the 
compound used as substrate. In most of the species CYP gene names are written in capital 
letters, while mouse and Drosophila Cyp gene names are lower-case, except for the first letter.  
Pseudogenes (genes that have lost their protein-coding ability) are identified with ‘P’ or ‘ps’ 
in mouse and Drosophila, after the gene number (Turpeinen, 2006; Werck-Reichhart & 
Feyereisen, 2000). 
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There are blocks of family names reserved for different taxonomic groups: families in the 
range 1-49 and 301-499 are for animals, 51-69 and 501-699 are for lower eukaryotes, 71-99 
and 701-999 are for plants, and 101-299 are for bacteria (Nelson et al., 1996; D. Nelson, 
2008; Werck-Reichhart & Feyereisen, 2000). 
 
 
1.4.4. Classification and species differences 
 
The basis of the CYPs unifying nomenclature system is founded on divergent evolution and 
sequence similarity, resulting in different families and sub-families. However, it does not 
encompass any classification or description of the substrate specificities or catalytic activities, 
although some broad generalizations can be done (see table 8) (Gibson & Skett, 2001; D. 
Nelson, 2008; Smith, Abel, Hyland, & Jones, 1998). 
In mammals, CYP enzymes can be divided in two classes. One group of enzymes involved in 
biosynthesis of regulators of various biological functions (e.g. steroid hormones) and another 
group responsible for metabolism of xenobiotics (see table 8). Although CYP1, CYP2 and 
CYP3 families are considered to metabolize mainly xenobiotics, they also have endogenous 
substrates, such as steroids, fatty acids, bile acids, eicosanoids and retinoids (Turpeinen, 2006; 
Zuber et al., 2002). 
Despite the similarities within CYPs families, it is found a high polymorphism in CYP genes 
of the same species and also significant species differences in the expression level of 
individual enzymes and their substrate specificity. It has not been found inherited patterns of 
CYPs expression between groups of animals that share other physiological features (e.g. 
carnivorous species). For example, dogs possess several unique CYP450 isoenzymes such as 
a canine form of CYP1/2, CYP2B11, CYP2C21 and 2C41, 2D15, 3A12 and 3A26 (Fink-
Gremmels, 2008). 
Generally, studies comparing CYPs activity between species are conducted measuring the 
conversion of known CYP model substrates in liver microsomes. So, when the activity level 
of CYPs in the conversion of human model substrates is compared between species, it is 
obtained a wide range of different results. Therefore, the extrapolation of CYPs activity and 
specificity between species is limited and not well studied, especially in veterinary species. 
When the CYPs activity of different animal species is compared, it has been more consistent 
for CYP2E1>CYP1A2, CYP4A> CYP2D and CYP3A, however the extrapolation of substrate 
specificity has been inconsistent when applied to CYP2A, 2B and 2C families (Fink-
Gremmels, 2008; Turpeinen et al., 2007). 
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So, when a specific CYP reaction is compared between different species it may not 
correspond to the same CYP. For example, based on in vitro assays and antibody inhibition 
experiments the N-oxidation of irsogladine is catalyzed by CYP2C proteins in rat, dog and 
monkey microsomes but no metabolism was obtained by human CYP2C9 (Nakamura, Hirota, 
Morino, Shimada, & Uematsu, 1997). 
 
 
Table 8. Generalized functions of CYPs (Gibson & Skett, 2001; Turpeinen, 2006) 
CYP family Function 
CYP1-CYP3 Xenobiotic, drug and steroid metabolism 
CYP4 Fatty acid, prostaglandin, leukotriene metabolism 
CYP5 Thromboxane synthesis 
CYP7 Cholesterol 7α-hydroxylation and bile acid synthesis 
CYP8 Prostacyclin and bile acid synthesis 
CYP11 Cholesterol side chain cleavage + steroid 11β hydroxylase 
CYP17 Steroid 17α-hydroxylation 
CYP19 Aromatization of steroids 
CYP21 Steroid 21-hydroxylase 
CYP24 Vitamin D hydroxylation 
CYP26 Retinoic acid hydroxylation 
CYP27  Vit.D3 hydroxylation, and cholesterol and bile acid synthesis,  
CYP39 24-hydroxycholesterol 7-hydroxylase 
CYP46 Cholesterol 24-hydroxylase 
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1.4.4.1. CYP1 family 
 
This family has been identified in 41 animal species and it is constituted by 3 subfamilies 
(CYP1A, 1B and 1C) (Cytochrome P450 Knowledgebase, 2006). In humans is formed only 
by 3 enzymes, which are codified by different alleles, but no pseudogenes have been found. 
The only enzyme of this family present in liver is CYP1A2, which is described in the next 
topic. The other two enzymes are CYP1A1 and CYP1B1, of which CYP1A1 is the major 
human extrahepatic CYP form; however it can be present at very low levels in human liver. 
CYP1B1 enzyme is undetectable in liver, but CYP1B1 mRNA is expressed, and it is present 
in almost every other tissue, such as kidney, prostate and breast (Ingelman-Sundberg, Daly, & 
Nebert, 2008; Phillips & Shephard, 2006; Turpeinen, 2006). 
In other animals, CYP1A enzymes seem to be somewhat different from the human CYP. For 
instance, in dogs the antibodies against human CYP1A were shown to influence microsomal 
6-hydroxylation of chlorzoxazone that is a typical activity of CYP2E1 in humans (Fink-
Gremmels, 2008).  
Enzymes in the CYP1 family are regulated by the AhR-receptor and are inducible after being 
exposed to polycyclic aromatic hydrocarbons (PAHs), found in cigarette smoke, and by 
2,3,7,8-tetrachlorodibenzo-p-dioxin. The compound α-naphthoflavone acts as a potent 
inhibitor of this CYP family (Phillips & Shephard, 2006). 
Besides detoxification, the CYP1 enzymes are often responsible for metabolic activation of 
PAHs and aromatic amines, which may be linked to chemical carcinogenesis (Sparfel, Van 





The CYP1A2 has been identified at least in 15 animal species (e.g. mouse, guinea pig, rabbit, 
chicken, cat and dog) and they share highly homologous amino acid sequence (Cytochrome 
P450 Knowledgebase, 2006). The typical substrates are aromatic structures, preferably 
aromatic amines, but also polycyclic aromatic hydrocarbons and other planar structures 
(Lewis, 2003). 
In humans is expressed mainly in liver and in a lower level in lungs along with CYP1A1. 
Despite the quite low quantitative proportion of CYP1A2 in liver, it has a major role in the 
metabolism of several compounds, such as ethoxyresorufin, caffeine (Rasmussen & Brosen, 
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1996), clozapine (Pirmohamed, Williams, Madden, Templeton, & Park, 1995), phenacetin 
(Tassaneeyakul et al., 1993) and theophylline (Ha, Chen, Freiburghaus, & Follath, 1995). 
This form is inducible by polycyclic aromatic hydrocarbons as 3-methylcholanthrene or by 
polychlorinated biphenyls, cigarette smoking, cruciferous vegetables and charcoal-grilled 
food (Lewis, 2003). Potent inhibitors of CYP1A2 include fluoroquinolones like ciprofloxacin 
(Batty, Davis, Ilett, Dusci, & Langton, 1995; Granfors, Backman, Neuvonen, & Neuvonen, 
2004), fluvoxamine (Yao et al., 2001), oral hormone replacement therapy and contraceptives 
(Lewis, 2003; Olavi Pelkonen et al., 2008). 
In domestic animals, CYP1A2 is especial important in cats. This species is highly susceptible 
to toxic effects from many drugs, regarding his deficient ability to form glucuronide 
conjugates. On the other hand, in some cases it is due not only to deficiency in 
glucuronidation, but also to the kinetic properties of CYP1A2. For instance, phenacetin is 
metabolized slower by feline CYP1A2 when compared with other species. Thus, the toxic 
effects of phenacetin metabolites are prolonged and severe in domestic cats due to both 
glucuronidation deficiency and the catalytic properties of CYP1A2 (see figure 10) (Tanaka, 
Miyasho, Shinkyo, Sakaki, & Yokota, 2006). 
 
Figure 10. Metabolic pathways of phenacetin (modified from Tanaka et al., 2006). 
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1.4.4.2. CYP2 family 
 
In CYP2 family has been identified at least 31 genes and 27 subfamilies among 10 animal 
species (Cytochrome P450 Knowledgebase, 2006). In humans 9 subfamilies are known 
(CYP2A, 2B, 2C, 2D, 2E, 2D, 2J, 2R, 2S and 2W), however they do not share any common 
regulation patterns and their substrate specificities and tissue expression vary substantially. At 
least five of those subfamilies (CYP2A-E) contribute significantly to drug metabolism. 
However the only functional enzymes in these subfamilies are CYP2B6, CYP2D6, and 
CYP2E1, whereas CYP2A contains two, and CYP2C four functional members. In other 
animal species, those human enzymes can not be identified but there are other active 
enzymes, such as in rat (CYP2B1/2), rabbit (CYP2B4/5) and dog (CYP2B11) (Ingelman-





In humans, CYP2A6 is expressed in different levels among the population and quantitatively 
is a minor component among hepatic CYPs. It does not have a large substrate base; usually 
they are structurally small and planar molecules (e.g. coumarin and nicotin). Nevertheless, 
this enzyme has a main role in drug metabolism and is also involved in the bioactivation of 
some toxic compounds such as aflatoxin B1 (Kuilman, Maas, & Fink-Gremmels, 2000) and 
nitrosoamines (Bonate & Howard, 2004; Turpeinen, 2006). 
Several inhibitors with variable selectivity are known (e.g. tranylcypromine and 
methoxysalen). However, the regulation mechanisms of this enzyme are not well known 
(Olavi Pelkonen et al., 2008). 
This CYP is of special interest in human and pigs. In humans there are several variant 
CYP2A6 alleles with distinct frequencies between ethnic groups, which have been associated 
with altered nicotine pharmacokinetic and furthermore to differing smoking habits 
(Mwenifumbo & Tyndale, 2007; Olavi Pelkonen et al., 2008). 
In pigs, CYP2A6 is linked to development of the phenomenon boar taint. This is 
characterized by high concentrations of androstenone and skatole (3-methylindole) stored in 
the fat tissues, which give undesirable taste and odor to the meat from sexually mature male 
swine. Sex and age differences in skatole level are related to an inhibitory effect of 
androstenone (and possibly some other sex steroids) on the expression of the skatole-
metabolizing enzymes CYP2A6 and CYP2E1. The low CYP2A6 and CYP2E1 expression 
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lead to a reduced rate of the hepatic skatole clearance with the consequent accumulation of 
skatole in adipose tissue (Babol, Squires, & Lundstrom, 1998; Chen, Cue, Lundstrom, Wood, 





CYP2B6 has a high polymorphic expression and it is affected by genotype, gender and 
ethnical group. This enzyme represents approximately 1-10 % of the total hepatic CYP and 
plays an important role in the hepatic metabolism of structurally diverse drugs, e.g. bupropion 
(Faucette et al., 2000), cyclophosphamide (Chang, Weber, Crespi, & Waxman, 1993) and 
ifosphamide (Granvil, Madan, Sharkawi, Parkinson, & Wainer, 1999). The usual substrates 
metabolized are non-planar, neutral, or weakly basic molecules with one or two hydrogen 
bond acceptors. However, in other species those substrates are metabolized by different 
CYPs. For instance, the canine orthologous of CYP2B6 (human) is CYP2B11 and the porcine 
homologue is CYP2B22 (72% of cDNA homology). Therefore, there is no clear ranking 
between species (Fink-Gremmels, 2008; Pasanen, 2004; Turpeinen, 2006). 
This CYP in humans is inducible via CAR- and apparently PXR-associated mechanisms, by 
phenytoin (Ducharme, Bernstein, Granvil, Gehrcke, & Wainer, 1997) phenobarbital and 
rifampin (Chang, Yu, Maurel, & Waxman, 1997). There are also several drugs with ability to 
inhibit it, e.g. orphenadrine and antiretroviral drugs (ritonavir, efavirenz, and nelfinavir) 
(Olavi Pelkonen et al., 2008). 
 
 
1.4.4.2.3. CYP2C subfamily 
 
In humans, CYP2C family comprises about 20% of the total hepatic CYP and, as already 
referred, there are only four functional enzymes (2C8, 2C9, C18, 2C19), which have more 
than 80% identical amino acid sequences (D. Nelson, 2008; Phillips & Shephard, 2006). 
In animals a huge species-dependent differences within this family can be observed. The level 
of activity of CYP2C family, between species, by comparing diclofenac-4’-hydroxylase 
activity, is higher in humans, followed by monkey and rat > rabbit > mouse > micropig > dog 
(Fink-Gremmels, 2008; Pasanen, 2004). 
 
 




CYP2C8 is present at relatively high levels in human liver and also plays a major role in drug 
metabolism, e.g. amodiaquine (X. Li, Bjorkman, Andersson, Ridderstrom, & Masimirembwa, 
2002), paclitaxel (Václavíková, Horský, Šimek, & Gut, 2003), cerivastatin (Muck, 2000) and 
repaglinide (Bidstrup, Bjornsdottir, Sidelmann, Thomsen, & Hansen, 2003). The reaction 
quantified as a marker activity for polymorphically expressed CYP2C8 in humans is 
paclitaxel 6-hydroxylation (Phillips & Shephard, 2006). However using the same substrate 
specificity study no such counterpart has been identified in other species (Pasanen, 2004). 
This CYP can be inhibit by several pharmaceutical compounds, e.g. quercetin (K.-A. Kim, 
Park, Kim, Ha, & Park, 2005), montelukast (K. Kim, Park, Kim, & Park, 2006), zafirlukast 
(Jaakkola, Backman, Neuvonen, Niemi, & Neuvonen, 2006) and trimethoprim (normal 
clinical dose can inhibit CYP2C8-mediated metabolic clearance by about 26% to 80%) 
(Mikko Niemi, 2004). CYP2C8 induction is mediated via multiple nuclear receptors (CAR, 





CYP2C9 is the predominant CYP2C isoform expressed in human liver and highly 
polymorphic, which contributes to the wide interindividual variation in the pharmacokinetic 
of certain drugs. So, this enzyme is responsible for metabolize several clinically relevant 
drugs: celecoxib (Kirchheiner et al., 2003), cyclophosphamide (Timm et al., 2005), 
ifosphamide (Chang, Yu, Goldstein, & Waxman, 1997), losartan (Stearns, Chakravarty, Chen, 
& Chiu, 1995), S-warfarin (Rai, Udar, Saad, & Fleisher, 2009) and several NSAID’s (Phillips 
& Shephard, 2006). The importance of the CYP2C9 polymorphism has a major role in S-
warfarin metabolism, which uses CYP2C9 as a major metabolic pathway and possesses a 
narrow therapeutic window with a fatal side-effect profile (Turpeinen, 2006). 
The catalytic activity of this CYP can be quantified by measuring S-warfarin 7-hydroxylation, 
diclofenac 4’-hydroxylation or tolbutamide 4’-hydroxylation activity (Phillips & Shephard, 
2006). However these reactions are performed by different CYP enzymes depending on the 
species, e.g. dog orthologous of CYP2C9 is CYP2C21. For instance, when tolbutamide 4’-
hydroxylation activity levels among different species is compared higher activity has been 
found in horse than man and dog, and the lowest activity in cat (Fink-Gremmels, 2008). 
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Among the inhibitors known for CYP2C9 in humans are gemfibrozil (Tornio, Niemi, 
Neuvonen, & Backman, 2007), amiodarone, sulphaphenazole and certain other 
sulphonamides (Miners & Birkett, 1998). 
The mechanism responsible for CYP2C9 induction is dependent on multiple regulatory 
elements (Olavi Pelkonen et al., 2008), e.g. rifampicin induces CYP2C9 via the PXR pathway 





CYP2C19 is only present in humans and handles a smaller proportion of all available drugs 
(~5%) (Musana & Wilke, 2005). So, CYP2C19 substrates include antiepileptics (phenytoin, 
mephenytoin), benzodiazepines (diazepam, flunitrazepam), tricyclic antidepressants 
(imipramine, clomipramine), selective serotonin receptors inhibitors (citalopram, sertraline) 
and proton pump inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole) (FDA, 
2006; Musana & Wilke, 2005; Olavi Pelkonen et al., 2008).  
The reactions used as marker activities for CYP2C19 are S-mephenytoin 4-hydroxylation and 
tolbutamide methyl hydroxylation. No selective drug inhibitors for CYP2C19 have been 
found yet, only fluvoxamine and fluoxetine have been reported as moderate inhibitors 
(Jeppesen et al., 1996). CYP2C19 is known to be inducible by chemicals, which act as 
ligands/activators for PXR and CAR, e.g. rifampin (Turpeinen, 2006). 
 
 
1.4.4.2.4. CYP2D subfamily 
 
Mammalian CYP2D genes are currently available for humans, apes, mouse, rat, rabbit, dog, 
pigs, cattle and others (see figure 11). Those vary tremendously among different species, with 
respect to the number of functional genes and pseudogenes, and the function and expression 
of their enzymes. However, in some species it can be found orthologous forms to human 
CYP2D enzymes with some similar functions (Cytochrome P450 Knowledgebase, 2006; 
Pasanen, 2004). 
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Figure 11. Phylogenetic tree of CYP2D subfamily genes. (Adapted from C.  Ioannides, 2008). 
 
 
One unusual feature in CYP2D subfamily is the extensive rodent subfamily, especially in 
mice, however the reason is not completely understood. The last data suggests that it may be 
due to selective pressure from the diet or/and an influence of endogenous pathways (C.  
Ioannides, 2008). Those could lead the evolution of CYP2D substrate specificities to an 
adaptive evolution, with the goal to fix mutations that enhanced protein-protein interactions as 
well as to fix mutations that allow the expansion of substrate specificity and increase the 
number of binding modes (Zawaira, Matimba, & Masimirembwa, 2008). 
Another distinctive characteristic in this subfamily is the porcine CYP2D25, which shares 
77% identity with human CYP2D6 (Hosseinpour & Wikvall, 2000). CYP2D25 has been 
recognized as a vitamin D3 25-hydorxylase, which is unique among CYP2D subfamily 
(Hosseinpour & Wikvall, 2000; C.  Ioannides, 2008). 
 
 




CYP2D6 gene is the most polymorphic of all known human CYPs, with more than 75 
polymorphisms identified (Musana & Wilke, 2005). It appears that 4 alleles account for >95% 
of the functional variation, being responsible for an important variability in CYP2D6 enzyme 
activity, ranging from complete deficiency (high risk for ADRs) to extensively increased 
activity (non-responsiveness to treatments) (Musana & Wilke, 2005; Turpeinen, 2006). 
Therefore, it is the most studied CYP with respect to pharmacogenetics (Turpeinen, 2006). 
CYP2D6 metabolizes approximately 20% of all commonly prescribed drugs. Examples 
include beta-blockers (carvedilol, S-metoprolol, timolol), antidepressants (amitriptyline, 
clomipramine, desipraminea) and a variety of antipsychotics (amitriptyline, haloperidol, 
codeine, dextromethorphan, lidocain, metoclopramide) (FDA, 2006; Flockhart, 2008; Musana 
& Wilke, 2005). So, typical reactions performed by CYP2D6 include the codeine O-
demethylation, haloperidol N-dealkylation and propranolol 4-hydroxylation (Uetrecht & 
Trager, 2007). 
CYP2D6 is inhibited by a wide range of drugs, of which a large proportion is also a substrate. 
The stronger inhibitors (more than 80% decrease in clearance) are bupropion, fluoxetine, 
paroxetine and quinidine (Flockhart, 2008). 
In contrast with most of other CYPs, no environmental agent or drug inducer are known – 
although physiological conditions such as pregnancy have been shown to increase the rate of 
CYP2D6-mediated metabolic reactions (Turpeinen, 2006). 
The species and CYP that share more similarities with human CYP2D6 is the Japanese 
monkey CYP2D29, however it shows higher liver microsomal expression than humans. In 
rats, CYP2D1 is the orthologous form to human CYP2D6, sharing 82% amino acid sequence. 
In mice, CYP2D22 was suggested to be the orthologue to human CYP2D6, but its catalytic 
properties towards some typical substrates and inhibitors were unique, which makes it more 
closely resemble to CYP3A4. The major CYP2D in dog is CYP2D15, which have some 
similar enzymatic activities with human CYP2D6 but showing some specific differences (e.g. 
very low debrisoquine hydroxylase activity) (Fink-Gremmels, 2008; Costas Ioannides, 2006; 
Pasanen, 2004). 
So, regarding all species differences in CYP2D composition and substrate specificity, it has 








CYP2E1 is a highly conserved gene and the only of its subfamily among most mammals, with 
the exception of rabbits and felines (see figure 12) (C.  Ioannides, 2008; Tanaka et al., 2005).  
The enzyme is constitutively expressed in hepatic tissue and in a lower concentration by 
extrahepatic tissues (lung, kidney, brain, nasal mucosa, bone narrow and peripheral blood 
lymphocytes).  
 
Figure 12. Phylogenetic tree of CYP2E subfamily of various species (Adapted from Tanaka et al., 2005) 
 
 
CYP2E1 exhibits very broad substrate specificity, but metabolizes only few drugs - 
contributing mainly to the metabolism of those that are metabolized primarily by other CYPs, 
for instance it can act as an alternative demethylation pathway for a variety of substrates 
metabolized by CYP3A4 (Tanaka et al., 2005; Turpeinen, 2006). However, this enzyme is 
also responsible for the metabolic activation of a large number of compounds into toxic 
metabolites. The substrates of CYP2E1 usually consist of hydrophobic and low molecular 
weight compounds, such as chlorzoxazone, benzene, ethanol, carbon tetrachloride, 
chloroform and anesthetics (enflurane, halothane, methoxyflurane) (Gonzalez, 2005; C.  
Ioannides, 2008). For modeling purposes of CYP2E1, chlorzoxazone 6-hydroxylation 
(Khemawoot, Nishino, Ishizaki, Yokogawa, & Miyamoto, 2007), N-nitrosodimethylamine N-
demethylation and p-nitrophenol hydroxylation (Phillips & Shephard, 2006) can be used to 
measure its catalytic activity. 
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This CYP plays a major role in xenobiotic metabolism and toxicity, owing to its substrate 
specificity. The main examples are: 1) major task in ethanol metabolism (C.  Ioannides, 2008); 
2) responsibility for initiating the cascade of toxic metabolites from acetaminophen; 3) 
requirement for the hepatotoxicity of chloroform and carbon tetrachloride; 4) ability to 
produce oxidative stress directly through NADPH oxidase activity and through metabolism of 
xenobiotics (Gonzalez, 2005). 
CYP2E1 expression is altered in response to a variety of xenobiotics, as well many different 
conditions, including gender, circadian rhythm (Khemawoot et al., 2007), nutrition (e.g. 
starvation and obesity), metabolic and endocrine disorders (e.g. diabetes), inflammation (in 
response to cytokines), viral infections (e.g. hepatitis C) and heppatocellular carcinoma (C.  
Ioannides, 2008). 
Mechanisms responsible for CYP2E1 regulation are complex, and involve intracellular 
signaling, transcriptional and post-transcriptional events and post-translational modifications. 
This CYP is inducible by several of it own substrates (e.g. ethanol, acetone, imidazol, benzene 
and isopropanol). Inhibitors of CYP2E1 include diethyl-dithiocarbamate (Guengerich, Kim, 




1.4.4.3. CYP3 family 
 
The CYP3 gene family includes the CYP3A and CYP3B subfamilies, however only the 
former is expressed by mammals (McArthur et al., 2003). 
Members of the CYP3A subfamily represent the dominant CYP forms expressed in the 
digestive and respiratory tracts, which are the first targets for ingested and inhaled foreign 
compounds, providing a broad biochemical defense and an important role in first-pass 
clearance (Vaz, Klabunde, & Published by 2008). 
This subfamily is responsible for the metabolism of a wide variety of chemical compounds 
(over 50% of all drugs in use today are substrates and/or inhibitors of mammalian CYP3A 
enzymes) and also metabolism of endogenous hormones, bile acids, fungal and plant 
products, and environmental pollutants (McArthur et al., 2003; Vaz et al., 2008). 
As happens in other species, this subfamily contains the most abundant CYP enzymes of the 
human liver, representing about 30% of hepatic content, and is the only CYP subfamily 
present in substantive amount in the enteric mucosa. The substrate specificity among this 
subfamily is broad, being considered the most important CYP subfamily in drug metabolism 
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(C.  Ioannides, 2008). It contains three functional enzymes (CYP3A4, CYP3A5, and CYP3A7) 
and one pseudoprotein (CYP3A43) (Bonate & Howard, 2004; Ingelman-Sundberg et al., 
2008; Olavi Pelkonen et al., 2008; Turpeinen, 2006). 
CYP3A5 is a minor polymorphic CYP isoform in human liver, with 25-40% of individuals 
expressing appreciable levels of this enzyme, but it is also expressed by other extrahepatic 
tissues (kidney, lung, colon, and oesophagus). It is structurally similar to CYP3A4, sharing 
most of its substrates and inhibitors, as well as with CYP3A7 (Pacifici & Pelkonen, 2001). 
CYP3A7 is the predominant CYP form in embryonic, fetal, and newborn livers, in contrast 
with its minor expression in adult liver. The main role during the fetal stage is the 
hydroxylation of several endogenous substances like retinoic acid and steroid hormones 





CYP3A4 has the sixth most transcribed CYPs mRNA in human hepatocytes, and the most 
abundant form found in human liver (between 30 and 60% of total CYP in liver, depending 
on many factors, as genetics and food). Though it is also expressed in other several tissues, 
with the expression in the liver and small intestine of primary interest (Vaz et al., 2008; Zuber 
et al., 2002). 
This CYP has an active site of sufficient size and topography to accommodate either large 
ligands or multiple smaller ligands (Scott & Halpert, 2005; Williams et al., 2004). Thus, 
CYP3A4 substrates vary widely in size and structure from small molecules such as 
acetaminophen to extremely large compounds such as cyclosporine A. In addition, among the 
other substrates are several therapeutic classes of drugs, such as macrolide antibiotics (e.g. 
clarithromycin, erythromycin), benzodiazepines (e.g. diazepam, midazolam), prokinetic 
(cisapride) and calcium channel blockers (e.g. amlodipine, verapamil); as well as several 
endogenous agents including testosterone, progesterone, androstenedione, and bile acid. 
Hence, it is possible that many of those substrates may compete and the risk of drug 
interactions is possible (FDA, 2006; Ingelman-Sundberg et al., 2008; Olavi Pelkonen et al., 
2008). 
CYP3A4 expression can be modulated by several factors, like diet components, hormones, 
drugs and genetic polymorphism. In addition, the nuclear receptors pregnane X receptor 
(PXR) and constitutive androstane receptor (CAR) have been shown to be involved in the 
inductive mechanism (Goodwin, Hodgson, D'Costa, Robertson, & Liddle, 2002; Rodrigues, 
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2008). This enzyme is inducible by a large number of substances, e.g. phenobarbital, 
glucocorticoids (dexamethasone), rifampin and St. John’s wort. It can also be inhibited by 
several compounds including certain azole antifungal agents (ketoconazole, itraconazole), 
antibacterials (clarithromycin, erythromycin), antihypertensives (verapamil, diltiazem) and 
food constituents (grapefruit juice, bergamottin) (Pacifici & Pelkonen, 2001; Olavi Pelkonen 
et al., 2008; Rodrigues, 2008). 
The most suitable animal CYP to an experimental model for CYP3A4-mediated metabolism 
was reported to be CYP3A29 in pigs. This CYP possesses a typical nifedipine hydroxylation 
and testosterone-6β-hydroxlylation activities (characteristic for CYP3A4) and it is inducible 
by phenobarbital, rifampin and dexamethasone (Soucek, Zuber, Anzenbacherova, 
Anzenbacher, & Guengerich, 2001; Zuber et al., 2002). 
 
 
1.5. Drug interactions 
 
Drug interaction occurs when the activity of a drug is affected by another drug or a food 
component. Thus, drug interactions can be classified in drug-drug interactions (DDI) or food-
drug interactions (FDI). These interactions are the consequence of alterations in 
pharmacokinetic or pharmacodynamics properties of the drug (Manzi & Shannon, 2005; 
Turpeinen, 2006). 
Pharmacodynamics interactions can be the result of the administration of receptor agonists 
(pure or partial) or antagonists (competitive or non-competitive), or it can be by interference 
in signal transduction (Ionescu & Caira, 2005).  
Pharmacokinetic interactions can take place at any level of the absorption, distribution, 
metabolism, or excretion process. The most clinically relevant interactions occur mainly in 
either absorption or metabolism phase (Olavi Pelkonen et al., 2008; Turpeinen, 2006).  
In metabolism phase, CYPs are the main system involved in metabolic drug interactions. This 
may be affected by either enzyme induction or enzyme inhibition. Consequences of CYP-
associated drug interactions resulting from reduced (inhibition) or increased (induction) rate 
and extent of the biotransformation will be discussed in more detail in following topics 




      40 
 
1.5.1. Inhibition of CYP enzymes 
 
Inhibition of CYP enzymes is the most common cause of DDI. The main interferences 
involved in CYP inhibitions are either the blocking of enzymatic synthesis, the destruction of 
pre-formed enzymes, or inactivation of the enzyme by their complexation with drug 
metabolites. The direct consequence can be: delay in drug metabolism, increased 
bioavailability of the parent compound; or prolongation of their pharmacological action by 
decreased elimination of compounds dependent on metabolism for systemic clearance. The 
type of CYP inhibition can be either irreversible or reversible (Ionescu & Caira, 2005; Olavi 
Pelkonen et al., 2008; Turpeinen, 2006). 
The half maximal inhibitory concentration (IC50) is used as a measure of how effective is the 
inhibition, which can be determined constructing a dose-response curve and examining the 
effect of different concentrations of inhibitor on CYP-related activity. In a broad sense, the 
obtained IC50 values are used for ranking purposes within one compound series and binned 
into classes exhibiting a high (IC50<1 µM), a moderate (1 µM <IC50<10 µM) and a low 




a. Reversible inhibition 
 
The latter is the most common type of enzyme inhibition. It is characterized by action of 
inhibitors that compete with substrates for occupancy of the active site.  The binding forces 
involved are usually weak, which are both formed and broken down easily. Consequently, 
reversible inhibitors act fast, but do not permanently destroy the enzyme. Four different types 
of reversible inhibition can be distinguish (Ionescu & Caira, 2005; Olavi Pelkonen et al., 
2008): 
• Competitive inhibition: Both the inhibitor and the substrate compete for the same site on 
the enzyme. It may be prevented if the active site is already occupied by the substrate; 
• Non-competitive inhibition: the active binding site of the substrate and inhibitor is 
different from each other; 
• Uncompetitive inhibition: the inhibitor only binds to the enzyme-substrate complex and 
not to the free enzyme; 
• Mixed-type inhibition: when elements of both competitive and non-competitive 
inhibition mode is observed. 
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b. Irreversible inhibition 
 
In contrast irreversible inhibition requires biotransformation of the inhibitor. So, the common 
step in this mechanism is the metabolic activation of a substrate into a metabolite. It can be 
trapped permanently within the active site of the CYP by: 1) forming a tightly bound 
complex, or; 2) via the strong covalent binding of reactive intermediates to the protein or 
heme of the CYP (Vaz et al., 2008). The only way to restore the enzymatic activity is though 
the new synthesis of the enzyme, that’s why this mechanism is also called “mechanism-based 
inhibition”, “metabolite base inhibition” or “suicide inhibition”. Mechanism-based CYP 
inhibition is time dependent and it also depends on substrate concentration and many times it 
needs the presence of NADPH (Olavi Pelkonen et al., 2008). 
 
 
1.5.2. Induction of CYP enzymes 
 
The induction of CYPs is highly conserved and is found not only in humans but also among 
other animal species. Induction is defined as an increase in enzyme activity as a consequence 
of an increment in gene transcription and intracellular enzyme concentration. In contrast with 
CYP inhibition, induction is a slow regulatory process involving nuclear receptors - aryl 
hydrocarbon receptor (AhR), pregnane X receptor (PXR) (figure 13), constitutive androstane 
receptor (CAR) - but also other transcription factors including peroxisome proliferator-
activated receptor (PPAR), farnesoid X receptor (FXR), liver X receptor (LXR), hepatic 
nuclear factor (HNF) family members, glucocorticoid receptor (GR), and CCAAT/enhancer-
binding proteins (C/EBPs) (Leslie M. Tompkins, 2007; Olavi Pelkonen et al., 2008). 
The stimulation of enzyme activity represents a temporal process and a protective response 
increasing the detoxification activity. The direct consequence is an accelerated rate of 
biotransformation of both endogenous compounds and xenobiotics. Regarding drug 
metabolism, it usually leads to therapeutic failure (subtherapeutic levels) and contributes to 
inter- and intra-individual variation in drug efficacy and potential toxicity associated with 
drug-drug interactions. 
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Figure 13. Schematic model of a xenobiotic binding and activating PXR. The latter binds to DNA as a 
heterodimer with a retinoid X receptor alpha (RXR), leading to CYP3A4 induction (modified from Leslie M. 




A typical characteristic of inducers is the ability to induce a wide spectrum of CYPs and in 
some cases it can lead to auto-induction, which can interfere with any other compounds 
metabolized by the same enzyme. Classical CYP-inducers in human include carbamazepine, 
phenytoin, rifampicin, and St. John’s wort (Turpeinen, 2006). Also, in animals many CYP 
inducers have been characterized: polycyclic aromatic hydrocarbons (PAHs) (induces 
CYP1A), Phenobarbital (induces CYP2B and CYP3A), glucocorticoids and some of their 
antagonists (induces CYP3A), ethanol (induces CYP2E1) and peroxisome proliferators 
(induces CYP4A) (T. Li, 1997). However, most of those inducers may behave differently 
depending on the species. For instance, rifampin is a potent inducer in human and rabbit but is 
a very poor inducer in rat (Benedetti & Dostert, 1994). Another example is the benzimidazole 
derivative omeprazole, which is a potent inducer of CYP1A in human, but it doesn’t act as 
inducer in rodents (Lu & Li, 2001). In contrast, pregnenolone 16α-carbonitrile is a potent 





      43 
 
1.5.3. Food-drug interactions 
 
The concept that food agents could enhance or reduce drug metabolism has gained importance 
in human medicine only gradually in the last two decades. However, the same didn’t happen 
in veterinary medicine, which is still an unexplored field (Strandell, Neil, & Carlin, 2004). 
The list of nutritious compounds involved in food-drug interactions embraces several food 
and herbal sources. For instance, regarding food interactions, the fish oil can be consumed as 
part of fish or as food supplement. It has been found in in vitro studies that commercial fish 
oil (constituted by eicosapentaenoic acid, docosahexaenoic acid, other omega-3 acids, and D-
α-tocopherol) inhibits CYP2C19, 2D6 and 3A4. So, it may be possible to increase the 
bioavailability of some of their substrates (Strandell et al., 2004). 
Concerning the major role and many well-known herbal extracts in drug interactions, they can 
be classified apart as herbal-drug interactions, but still belonging to the group of food-drug 
interactions (Cott, 2008; Nowack, 2008). So, in the following topics it will be presented: 1) 
examples of herbal-drug interactions in humans that can be used as basis for studies in 
veterinary sciences, owing to the lack of information in this field; 2) description of some plant 
extracts and phytochemicals as possible CYP inhibitors, which were used in the present study 
and could also be used in further studies involving veterinary species. 
 
 
1.5.3.1. Herbal-drug interactions 
 
The natural products grapefruit (Citrus paradisi) juice and St. John’s wort (Hypericum 
perforatum) are usually the most cited examples responsible for drug interactions, involving 
either CYPs inhibition or induction. However, there are many other herbal components 
capable of affect CYPs activity, e.g. other close grapefruit relatives, wine, medicinal herbs 
and herbal teas (Nowack, 2008). 
The first documented food-drug interaction, in 1989, when grapefruit juice was first found to 
increase the blood levels of felodipine, a calcium channel blocker. Since then, it has been 
described to interfere with many other drugs metabolism (Cott, 2008). 
Grapefruit juice inhibits CYP1A2, CYP2C9 and most strongly intestinal CYP3A4 (Hidaka et 
al., 2008). CYP3A4 inhibition is a mechanism-based inhibition. It is caused by 
furanocoumarins (bergamottin, bergaptol and geranycoumarin), which bind to the enzyme as 
suicide substrates, and to a minor extent by flavonoids (naringin/naringenin). So, this 
mechanism is responsible for increasing the bioavailability of many drugs metabolized by 
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CYP3A4, e.g. nifedipine, verapamil, simvastatin, lovastatin, cyclosporine, triazolam and 
midazolam (Dahan & Altman, 2004; Girennavar, Jayaprakasha, Jadegoud, Nagana Gowda, & 
Patil, 2007; Kupferschmidt, Ha, Ziegler, Meier, & Krähenbühl, 1995; Nowack, 2008).  
The last studies suggest that the “grapefruit effect” extends also to pineapple juice and other 
close grapefruit relatives such as pomelos (Citrus grandis) and Seville oranges (Citrus 
aurantia), being also capable of CYP3A4 inhibition (Hidaka et al., 2008). 
Wine is a worldwide consumed drink with many phytochemically brands available. Red wine, 
but not white wine, is responsible for CYP3A4 inhibition. One of its constituents, revesterol 
acts as a mechanism-base inhibitor. It has been reported to decrease the bioavailability of 
cyclosporine in humans (Tsunoda, Harris, & Christians, 2001). 
St. John’s wort is widely used for the treatment of concussion depression (mild to moderate) 
(Stargrove, Treasure, & McKee, 2007). However, it has been reported to cause several herd-
drug interactions. These interactions are caused by induction of the drug transporter P-gp and 
both intestinal and hepatic CYP3A4, through activation of the nuclear receptor PXR (Cott, 
2008; Tannergren et al., 2004). The CYP3A4 induction accelerates the clearance of its 
substrates, decreasing their bioavailability, e.g. cyclosporin, simvastatin, midazolam, 
omeprazole, theophylline and verapamil (Nowack, 2008; Tannergren et al., 2004). 
In addition, St. John’s wort can inhibit some CYPs (e.g. CYP1A2, 2C9, 2C19, 2D6 and 3A4). 
Therefore, first it may leads to an increased bioavailability of the CYP3A4 substrates (owing 
to the inhibition), but then is followed by a decrease in bioavailability as consequence of the 
PXR-mediated induction (slow regulatory process) (Nowack, 2008). 
There are many other medicinal herbs or herbal teas which may induce or inhibit CYPs 
activity, such as: camomile (Matricaria recutita), peppermint (Mentha piperata), dandelion 
(Taraxacum officinale), ginkgo (Ginkgo biloga), siberian ginseng (Eleutheroccus senticosus), 
milkthistle (Sylibum marianum), saw-palmetto (Serenoa repens), echinacea (Echinacea 
purpurea), black cohosh (Cimicifuga racemosa), valerian (Valeriana officinalis), soya 
(Glycine max) and goldenseal (Hydrastis canadensis) (Nowack, 2008; Strandell et al., 2004). 
For instance, ginkgo has shown to inhibit a large number of CYPs (CYP1A2, 2C9, 2C19, 2D6 
and 3A4) in vitro and is responsible for mechanism-based inhibition of CYP3A in rats (Zhou 
et al., 2003). Goldenseal is a medicinal herb used in humans and animals regarding its 
immunomodulatory and anti-inflammatory properties. However, it is a strong inhibitor of 
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1.5.3.2. Plant extracts with possible CYP inhibition properties 
 
Regarding the importance of plants in human and animal diet, and the lack of knowledge in 
herbal-drug interactions, continued survey and research is essential. So, in the present thesis 
was analyzed five different plant extracts available in food supplies that can be ingested by 
both humans and animals. This study was conducted as a first surveillance test using human 
microsomes, owing to a bigger importance and development of this area in human medicine 
than in veterinary medicine. Nevertheless, the final results can also be used in further studies 
involving veterinary species. 
The plant extracts analyzed are: 1) bark and phloem extracts from Pinus sylvestris (common 
name Scotch pine); 2) root extracts from Angelica archangelica (common name Angelica);  
3) extracts from Citrus grandis (also known as Citrus maxima and by the common name 
Pomelo); 4) two different types of Mentha sp. (common name Mint) extracts by using water 
and ethanol as their solvents. 
Most of these plants are used as food additives. For instance, Pinus sylvestris is used as a 
flavoring ingredient and adjuvant, permitted for direct addition to food for human 
consumption. In Scandinavian countries and Germany it is available as an aqueous extract 
from the pine needles. In many countries, Angelica archangelica is used as a flavoring 
ingredient and a food ingredient. Mentha sp. has many uses, such food ingredient, tea and oil 
extracts. Pomelo is an asian tree and only the fruits are consumed (Duke, 2008). 
 
 
1.5.3.3. Phytochemicals with possible CYP inhibition properties 
 
Nowadays, the use of purified phytochemicals as a food supplement is a common routine in 
the alimentary industry, or they can be used as part of medical treatments. In this study was 
analyzed compounds of two chemical groups (furocoumarins and monoterpenes), which will 





Furocoumarins (or furanocoumarins) are a class of phytochemicals produced by a variety of 
plants as part of their defense mechanisms against predators, ranging from insects to 
mammals. Their chemical structure consists of a furan ring fused with coumarin. The former 
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may be fused in different ways producing several isomers. Some of the furocoumarins have 
been already identified as CYP inhibitors and responsibles for FDI (Zhou et al., 2003). 
In this study, two structural classes of furocoumarins, angular and linear, were used. The 
angular furocoumarins used were: 5,6-dihydroxyangelicin, sphondin, lanatin, isobergapten 
and angelicin. The phytochemicals belonging to the linear class of furocoumarins used were: 
8-hydroxybergapten, phellopterin, cnidilin, bergaptol, isopimpinellin, bergamottin, 
imperatorin, psoralen, bergapten and xanthotoxin. 
5,6-Dihydroxyangelicin is a natural angular furocoumarins isolated from the root of Angelica 
glabra makino and from the fruits of Ligusticum acutilobum (Duke, 2008). 
Sphondin is found in Angelica archangelica and also in the root of Heracleum laciniatum and 
Pastinaca sativa, being responsible for phototoxic reactions (Duke, 2008). 
Lanatin is a natural furocoumarins extracted from Heracleum thomsoni (Banerjee, 1980). 
Psoralen is a photosensitizing agent found in several plants and it has an important use in 
PUVA treatment (it is administered to sensitize the skin, after skin exposure to UVA light) for 
skin problems such as eczema, psoriasis, vitiligo, and mycosis fungoides. Some important 
psoralen derivatives are imperatorin, xanthotoxin and bergapten. Most furocoumarins can be 
regarded as derivatives of psoralen or angelicin. 
Bergaptol, bergapten and bergamottin are present in grapefruit juice, but they inhibit 
principally CYP3A4 in the intestine (Duke, 2008). 
Imperatorin and phellopterin can be found in several species of Angelica sp. and Citrus sp. 
(Duke, 2008). Specifically, imperatorin is present in the root of Angelica dahurica; in the 
fruits, leaves and roots of parsnip and Ammi majus L.; in lemon and lime oils; in the fruits of 
parsley, fennel and possibly coriander (Kleiner, Vulimiri, Starost, Reed, & DiGiovanni, 
2002). 
Isopimpinellin is found in healthy celery, in parsnip fruits, leaves, and roots; in the fruits of 
Ammi majus L. and in the rind and pulp of limes (Kleiner et al., 2002). 
Isobergapten and cnidillin are present in several plants, especially in Angelica sp. 8-





As part of this study pure α-thujone and mixed α-, β-thujone were tested as possible CYP 
inhibitors. Thujone is a ketone and a monoterpene that exists in two stereoisomeric forms: α-
thujone and β-thujone (more toxic). Thujone is a strong irritant and has cytotoxic properties. 
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Generally, it is considered to have antimicrobial, anthelmintic, uterine stimulant as well as 
psychedelic activity. Thujone is predominantly eliminated via kidneys and lungs. In nature it 
is present as a mixture of both and the proportion varies with the source. It occurs in the 
essential oils and parts of the plants of Thuja occidentalis (thuja), Artemisia absinthium 
(wormwood), Salvia officinalis (sage), Salvia sclarea (clary), Tanacetum vulgaris (tansy) and 
in Juniperus sp. and Cedris sp. Synthetic α-thujone is also available commercially in E.U.. 
However, this compound is most famous for being incorporated in the drink absinthe and 
some other alcoholic beverages. Owing to the possible neurotoxicity induced by thujone, in 
USA is not authorized for use as a flavoring substance and in E.U. it was set a maximum level 
(Annex II of Directive 88/388 EEC) (E.U., 2003). 
The thujone metabolism occurs mainly via 7-hydroxylation with lesser amounts of other 
hydroxylated metabolites. Nevertheless, different metabolic pathways have been observed in 
different species, for instance there was found site specificity and species differences between 
in mouse, rat and human liver microsomes (E.U., 2003). 
Thujone represents a major concern in veterinary medicine, owing to the ingestion of Thuja 
occidentalis and other plants containing thujone by wild and farm animals; and the use of 
ethanolic extraction of Thuja occidentalis as veterinary homeopathy treatment in food 
producing animals. 
In the summary report of Thuja occidentalis evaluation by the Committee for Medicinal 
Products for Veterinary Use (CVMP one of the European Agency for the Evaluation of 
Medical Products - EMEA - Committees) it is stated that the calculated worst-case residues of 
thujone in meat or milk are considered negligible compared to maximum limits established 
for plant foodstuffs or following use of flavourings. Nevertheless, it is not known the 
possibility of CYP inhibition by thujone, leading to a herbal-drug interaction (EMEA/MRL, 
1999). 
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2. Aims of the present study 
 
This thesis was developed in collaboration with the project “Food-drug interactions: exploring 
and pre-empting intricate health risks”, at the Institute of Biomedicine, University of Oulu. It 
consisted in the evaluation of plant extracts and phytochemicals as possible CYP inhibitors, 
using single substrate assays in vitro with human hepatic cromosomes. So, to establish a 
possible link or comparison between potencial inhibitions in humans and other animal 
species, two different studies were performed. The general aim was to explore the relation of 
CYPs activity between different species (human, rabbit, minipig and mouse) and to identify 
potential CYP inhibitors among several plant extracts, including purified herbal compounds. 
The specific goals included: 
1. To compare hepatic drug metabolism characteristics of humans with three different 
laboratory animal species (rabbit, minipig and mouse), measuring in vitro CYP 
activities (MultiCYP 7-ethoxycoumarin 0-deethylase (ECOD), CYP1A1/2 7-
ethoxyresorufin 0-deethylase (EROD), CYP2A6 coumarin 7-hydroxylase (COH), 
CYP3A4 midazolam 1-hydroxylase (OH-MDZ), and CYP2E1 chlorzoxazone 6-
hydroxylase (OH-CLZ); 
2. To investigate several herbal extracts and compounds as potential inhibitors of 
CYP1A1/2 (EROD), CYP2A6 (COH), CYP3A4 (OH-MDZ) activities in vitro. 
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Midazolam was kind donation from F. Hoffman-La Roche (Basel, Switzerland). Plant extracts 
and phytochemicals (table 9) were acquired from Division of Pharmacy, Department of 
Biochemistry and Pharmacy, Abo Akademi University. 7-ethoxyresorufin, 7-ethoxycoumarin, 
bovine albumin, chlorzoxazone, coumarin, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, NADP, NADPH, methanol, TCA and resorufin were obtained mainly from 
Sigma Aldrich (St. Louis, MO). The laboratory water was purified trough a Milli-Q system 
(Millipore S.A., Molsheim, France). 
 
Table 9. List of phytochemicals and plant extracts used in the study 
Phytochemicals  Plant extracts 
8-Hydroxybergapten Bergamottin  
5,6-Dihydroxyangelicin Imperatorin  
Pinus sylvestris 
(bark and phloem extract) 
Phellopterin Psoralen  
Sphondin Angelicin  
Angelica archangelica 
(roots) 
Cnidilin Bergapten  
Lanatin Xanthotoxin  
Mentha sp. 1 
Bergaptol α, β - Thujone  
Isobergapten α - Thujone  
Isopimpinellin   
Citrus grandis 
1 Two types of extraction, one using water as a solvent and the other using ethanol 
 
 
3.1.2. Liver samples 
 
Human liver samples used in the study were obtained from the University Hospital of Oulu as 
surplus from cadaver kidney transplantation donors. The collection of surplus tissue was 
approved by the Ethics Committee of the Medical Faculty of the University of Oulu, Finland. 
All donors were Caucasians. Animal liver samples were left-over tissue from untreated male 
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animals used as controls in other studies. All liver samples of human and animal origin were 
transferred to ice immediately after the surgical excision, cut into pieces, snap-frozen in liquid 
nitrogen, and stored at –80°C until the microsomes were prepared by standard differential 
ultracentrifugation (O. Pelkonen, Kaltiala, Larmi, & Karki, 1974). The previous method is 
used to separate certain organelles from whole cells for further analysis of specific parts of 
cells, subjecting to repeated centrifugations, each time removing the pellet and increasing the 
centrifugal force. The final microsomal pellet (pooled sample from all livers) was suspended 
in 0.1 M phosphate buffer pH 7.4. The protein content was determined by the method of 
Bradford (1976), which is a spectrophotometric analytical procedure used to measure the 
concentration of protein in a solution. Detailed data for the animal and human liver specimens 
are summarized in tables 10 and 11. 
 
Table 10. Characteristics of the animal liver samples used in the study. 
Species Number of liver samples Strain Age (weeks) 
Mouse 
(Mus musculus) 10 DBA/2N 8 
Minipig 
(Sus scrofa domesticus) 6 Goettingen 62–86 
Rabbit 
(Oryctolagus cuniculus) 3 New Zealand white 52–96 
 
Table 11. Characteristics of the human liver samples used in the study. 
Age (years) Sex Cause of death Drug history Liver pathology 
n.a. male gun shot no medication none 
n.a. female ICH1 no medication none 
54 male ICH diazepam2 none 
44 male ICH phenytoin2, alcohol abuse cirrhotic 
40 female ICH dexamethasone
2, 
nizatidine2, phenytoin2 none 
43 male ICH diazepam2, smoker none 
47 male ICH no medication, smoker none 
33 male astrocytoma not known none 
70 female melanoma not known steatosis 
52 male n.a.3 not known steatosis 
21 male stroke dexamethasone2, smoker none 
39 female ICH, SAH4 dexamethasone2 none 
53 female ICH, SAH no medication none 
44 female ICH, SAH no medication steatosis 
62 male ICH, SDH5 metformin, alcohol abuse, smoker steatosis 
1 ICH, intracerebral haemorrhage; 2 Drugs were administered only during the last 24 h before death; 3 n.a., not 
available; 4 SAH, subarachnoidal haemorrhage; 5 SDH, subdural haematoma. 
 




3.2.1. Evaluation of CYP-related activity 
 
3.2.1.1. Incubation conditions 
 
The following enzyme assays were employed: 7-ethoxyresorufin O-deethylation (ECOD), 
ethoxyresorufin-O-deethylation (EROD), coumarin 7-hydroxylation (COH), chlorzoxazone 6-
hydroxylation (OH-CLZ) and midazolam 1-hydroxylation (OH-MDZ). The following 
procedures were described in detail by Taavitsainen et al. (2001). 
All enzyme assays were carried out as individual assays and not as cocktail assays (with all 
substrate assays in the same incubation). Two parallel incubations and one control were 
performed for each liver sample. The reaction conditions were selected on the basis of 
experience with human livers. The substrate concentrations were chosen on the basis of 
known human Km values and were within the linear part of time and protein concentration-
dependence curve for the metabolite formations. The assay conditions and analytical methods 
are summarized in table 12. 
 









time (min) Assay method 
7-Ethoxycoumarin 
















1-hydroxylase 0,5 10 5 
UV-HPLC, 
245 nm 
1 Excitation (Ex) and emission (Em) 
 
In 7-ethoxycoumarin O-deethylation (ECOD) and coumarin 7-hydroxylation (COH) 
reactions, each incubation comprised: hepatic microsomes (volume of protein equivalent to 
the amount showed in table 12), 100 μL of cofactor mixture (1 part of 2M KCl, 1 part of 0.1M 
MgCl2, 2 parts of 0.03M glucose-6-phosphate, 1 part of 2.5mM NADP, 1 part of 0.114mg/mL 
glucose-6-phosphate dehydrogenase and 4 parts of 0.1M phosphate buffer pH=7.4) and 
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phosphate buffer pH=7.4 in a final volume of 0,5 mL. In the control samples was also added 
500 μL of TCA 6%. It was used as standard a mixture of 125 μL of 7-OH-Coumarin and 375 
μL of distilled water. All mixtures were pre-incubated for 2 min at 37°C in a shaking 
incubator block (Eppendorf Thermomixer 5436, Hamburg, Germany). The 7-ethoxycoumarin 
0-deethylase and coumarin 7-hydroxylation reactions were started by the addition of 10 μL of 
substrate (0,5mM 7-ethoxycoumarin or 0,5mM coumarin) and terminated after 10 minutes 
adding 500 μL of TCA 6% (not necessary in the control tubes) and subsequently cooled in an 
ice bath to precipitate proteins. The mixtures were vortex mixed and spun at 10 000 G for 10 
min. After the centrifugation 0.5 mL of supernatant was collected to be analyzed. 
In ethoxyresorufin O-deethylation (EROD) reaction was used the same amount of hepatic 
microsomes, 100 μL of bovine albumin (12 mg/mL), 250 μL of cofactor mixture (already 
described) and 0.1M Tris-HCl pH=7.8 in a final volume of 550 μL. In the control samples 
was also added 2.5 mL of methanol. It was used as standard a mixture of 100 μL of 0.01mM 
of resorufin, 250 μL of cofactor mixture, 550 μL of 0,1M Tris-HCl pH=7.8 and 100 μL of 
bovine albumin (12 mg/mL). All mixtures were pre-incubated for 2 min at 37°C, also in a 
shaking incubator. The reaction was started by mixing 100 μL of the substrate (10 μM 7-
ethoxyresorufin) and stoped after 5 minutes with 2.5 mL of cooled methanol. The mixtures 
were vortex mixed and spun at 10 000 G for 10 min. 
Chlorzoxazone 6-hydroxylation (OH-CLZ) reaction was prepared using hepatic microsomes, 
20 μL of 1mM chlorzoxazone and 0.1M phosphate buffer pH=7.4 in a final volume of 200 
μL. In the control samples was also added 200 μL of methanol. All mixtures were pre-
incubated for 2 min at 37°C, also in a shaking incubator. The reaction was started by mixing 
40 μL of cofactor mixture (already described) and stoped after 20 minutes with 200 μL of 
cooled methanol. The mixtures were vortex mixed and spun at 10 000 G for 15 min. All 
supernatants were colleted after centrifugation and stored at -20ºC for 24H to precipitate 
proteins. 
In midazolam 1-hydroxylation was used a similar procedure to chlorzoxazone 6-
hydroxylation. However, it was used 20 μL of 0.1mM midazolam as substrate; the reaction 
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3.2.1.2. Assay methodology 
 
3.2.1.2.1. Fluorimeter conditions 
 
7-ethoxycoumarin O-deethylation (ECOD), ethoxyresorufin O-deethylation (EROD) and 
coumarin 7-hydroxylation (COH) metabolite formation were measured by using a standard 1 
cm cuvette in a Kontron SFM5 fluorimeter with the excitation and emission values available 
in table 12. In ECOD and COH reactions, the analysis was performed by adding 2 mL of 
Glycine-NaOH and 0.5 mL of the supernatant already prepared. In EROD reaction, the 
analysis was performed directly in the supernatant isolated. 
CYP activities were obtained according to the following equations: 
 
Equation 2 and 3. Calculation of CYP-related activity 
 

















mgpmol μ  
Legend:  
µ - Average of fluorescence values of both parallel incubations, and minus the control incubation value 
Std - Fluorescence value of the standard; In both equations, numbers 10 and 5 correspond to the incubation 
period (minutes); Numbers 0.1 and 0.2 correspond to the protein concentration (mg.ml-1); The coeficient 
constants in each equation are respectively 1250 and 1000. 
 
 
3.2.1.2.2. HPLC conditions 
 
For midazolan 1-hydroxylase and chlorzoxazone 6-hydroxilation activity evaluation a Water 
Alliance chromatographic system with autosampler, vacuum degasser and column oven was 
used. The analytical column was a Waters XTerra MS C18, 2.1mm×50mm, 3.5 μm with 
Phenomenex Luna C18(2) precolumn, 4.0mm×2.0mm, 3.0 μm (Phenomenex, Torrance, 
California, USA). It was used an isocratic flow (the mobile phase composition remains 
constant), using a flow rate of 0.3 ml/min and the column oven temperature was 30ºC. The 
eluents used for chlorzoxazone 6-hydroxylation reaction were 70% 50 mM O-phosphoric 
acid-buffer and 30% acetonitrile. For midazolam 1-hydroxylase reaction the eluents were 
60% water and 40% acetonitrile. 
The quantification of metabolites, which represents the CYP-related activity, was obtained 
after being detected with HPLC. This quantification was directely provided by the 
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chromatographic system that performed a peak integration, using an internal calibration curve 
(it compares the unknown to a set of standard samples of known concentration).  
 
 
3.2.1.3.  Calculation of CYP-related activity 
 
The catalytic activity for each CYP and species were determined by the average of duplicate 
incubations and compared with the respective control incubation (incubation with denatured 
microsomes) by statistical analysis using SPSS Statistics 17.0. Results are expressed as means 
± standard deviation (SD) and coefficient of variation (CV%). 
 
 
3.2.2. Evaluation of CYP inhibition 
 
3.2.2.1.  Incubation and assay conditions 
 
Inhibition of human liver microsomes by various plant extracts and phytochemicals was 
studied in the incubation system described above: ethoxyresorufin-O-deethylation (EROD), 
coumarin 7-hydroxylation (COH) and midazolam 1-hydroxylation (OH-MDZ). However, it 
was added into the incubation system 2 μL (OH-MDZ) or 10 μL (EROD/COH) of 
phytochemicals in three different concentrations (1, 10 and 100 μM) and plant extracts (1, 10 
and 50 mg/mL). The final results were compared with a normal incubation that ran in parallel. 
 
 
3.2.2.2. Calculation of half maximal inhibitory concentration (IC50) 
 
IC50 values were determined adding one phytochemical at final concentrations of 1, 10 and 
100 μM or one plant extract at final concentrations of 1, 10 and 500 μg/mL to the incubation 
mixture. The resultant activities were compared with those from control incubations into 
which only solvent had been added. The solvent used was water (Pinus sylvestris, Angelica 
archangelica, Mentha sp.(water extraction) and Citrus grandis) or DMSO (Mentha sp. 
(ethanol extraction) and phytochemicals). The IC50 values (the concentration of inhibitor 
causing 50% inhibition of the original enzyme activity) were determined graphically by linear 
regression analysis of the plot of the logarithm of inhibitor concentration versus percentage of 
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activity remaining after inhibition using Origin, version 6.0 (Microcal Software Inc., 
Northampton, MA, USA). 
 
 
4. Results and discussion 
 
4.1. Interspecies comparison of in vitro activities of CYP-mediated metabolism 
 
This study was focused on the determination of CYPs activities in humans, rabbits, minipigs 
and mouses, towards probe substrates. 
It should be emphasized that all probe substrates used as enzymatic model reactions are 
mainly targeted to human CYPs. Nevertheless, similar probes have already been used to 
obtain animal CYP data in other individual studies (Fink-Gremmels, 2008; Pasanen, 2004; 
Turpeinen et al., 2007). 
 
Table 13. Estimated CYP-associated activities in hepatic microsomes of different species 1 
Human Rabbit Minipig Mouse Activity and metabolite 
abbreviation µ ± σ (1) CV% (2) µ ± σ (1) CV% (2) µ ± σ (1) CV% (2) µ ± σ (1) CV% (2)
7-Ethoxycoumarin 

















































1 Each value is the mean ± standard deviation of two replicates; 2 Coefficient of variation; 3 Activity measured in 
pmol.min-1.mg-1; 4Activity measured in μmol.min-1.mg-1 
 
Table 13 illustrates the results of different CYPs activities - 7-ethoxycoumarin 0-deethylase, 
ethoxyresorufin O-deethylation, coumarin 7-hydroxylation, chlorzoxazone 6-hydroxylation, 
and midazolam 1-hydroxylase - among different species in this study. All CYP activities 
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show low coefficients of variation. OH-MDZ in minipig shows the highest variation, followed 
by OH-CLZ in mouse. The standard deviation is zero in three cases, because in those 
situations only one of two replicates was not valid.  
 
Figure 14. Model CYP activities for each species studied. Values are the mean. Duplicate incubates for each of 




Despite the fact that it wasn't performed any inferential statistics, it is still possible to find 
some equalities between different species, as illustrated in table 13 and figure 14. 
7-Ethoxycoumarin-O-deethylation (ECOD) reaction is catalyzed in humans by several CYPs 
isoforms. Although it was found to have the lowest ECOD activity, which corresponds to 
23% of the value obtained in mouse liver microsomes that displayed the highest activity.    
Ethoxyresorufin-O-deethylation (EROD) reaction showed the highest similarity between 
mouse and minipig. Moreover, it only represents 30% of the activity in rabbit and 60% of the 
activity in humans. 
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Coumarin 7-hydroxylation (COH) reaction is catalyzed in humans by CYP2A6, in mice by 
CYP2A5 (Aoki et al., 2006), by CYP2A in minipigs (Soucek et al., 2001) and CYP2A10 in 
rabbits (Lee, Obach, & Fisher, 2003). Human CYP2A6 was found to have the highest COH 
activity and mouse CYP2A5 the lowest, which represents only 4% of COH activity in 
humans. Nevertheless, it represents 65% of rabbit CYP2A10 activity and 23% of minipig 
CYP2A activity. 
CYP2E1, which is highly conserved in mammals, is responsible for chlorzoxazone 6-
hydroxylation (OH-CLZ) reaction. In line with previous studies (Fink-Gremmels, 2008; 
Turpeinen et al., 2007), this reaction showed similar activities among the tested species, being 
possible to organize in two groups: human and mouse (which human CYP2E1 has 90% of 
mouse activity) versus rabbits and minipigs (which rabbit CYP2E1 has 94% of minipig 
activity). On the contrary OH-CLZ reaction in humans is 218% higher than in rabbits, and in 
minipigs is 230% higher than in mice. 
The midazolam 1-hydroxylase (OH-MDZ) reaction is performed by CYP3A4 in humans, 
which has demonstrated to have the highest catalytic activity. Mice have the lowest activity, 
only 6% of human OH-MDZ activity, followed by the rabbit and minipig that have 20% and 
27% each of them, when compared also with humans. 
The present results show extensive species differences in each catalytic activity studied, being 
possible to establish only sporadic catalytic similarities.  
 
 
4.2. CYP-related activity in the presence of plant extracts and phytochemicals 
 
The aim of this study was to identify plant compounds capable of inhibit CYP1A1/2 
(ethoxyresorufin-O-deethylation), CYP2A6 (Coumarin 7-hydroxylase) and/or CYP3A4 
(midazolam 1-hydroxylation), by measuring in vitro human CYPs activity in the presence of 
plant extracts. 
As already explained, the potencial inhibition of CYPs resulting of interactions with these 
compounds, was measured using the half maximal inhibitory concentration (IC50) values and 
classifying them in classes, exhibiting a high (IC50<1 µM), a moderate (1 µM <IC50<10 µM) 





      58 
 
4.2.1. Plant extracts 
 
Five different plant extracts were used as possible CYP inhibitors. They were bark and 
phloem extracts from Pinus sylvestris (common name Scotch pine), root extracts from 
Angelica archangelica (common name Angelica), extracts from Citrus grandis (also known 
as Citrus maxima and by the common name Pomelo) and two different types of Mentha sp. 
(common name Mint) extracts by using water and ethanol as their solvents. 
In the table below is presented CYP-related activity in the presence of plant extracts, wich 
data was used to determine the remain activity of the CYP and IC50 value, as presented in 
table 15 and figure 15. 
 
Table 14. CYP-related activity in the presence of plant extracts 







Control  65,73 706,65 185,00 
1 65,48 671,73 230,00 
10 36,18 556,73 105,00 Pinus sylvestris 
50 14,17 327,22 175,00 
1 9,12 608,35 159,50 
10 3,00 284,21 99,00 
Angelica 
archangelica 
50 0,88 383,83 26,00 
1 43,64 663,95 166,00 
10 11,39 574,59 136,50 
Mentha sp. 
(Ethanol extration) 
50 3,17 208,49 57,00 
1 59,06 654,68 179,50 
10 27,57 612,91 198,00 
Mentha sp. 
(Water extration) 
50 1,94 272,08 173,50 
1 47,19 658,36 214,50 
10 17,06 675,93 272,00 Citrus grandis 
50 3,89 534,21 200,50 
1 pmol.min-1.mg-1; 2 μmol.min-1.mg-1 
 
The ethoxyresorufin-O-deethylation (EROD) reaction performed by CYP1A1/2 is the most 
inhibited among the reactions analyzed. The Angelica archangelica extract has the highest 
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inhibitory effect in EROD reaction (lowest IC50). In general, the extract of this plant inhibits 
more effectively two out of three CYPs activities than the other plant extracts, as shown in 
table 15. 
On the contraries with the latter statement, the Pinus sylvestris interacts in a less potent 
manner with the CYPs studied. Nevertheless, it has been reported that a phytochemical 
(quercetin) in this plant is capable of inhibiting CYP1A2 (Duke, 2008). 
CYP3A4 (midazolam 1-hydroxylation), which is the most important human CYP in drug 
metabolism and susceptible of FDI, only suffers inhibition by high levels of the Angelica 
archangelica extract. 
The ethanol extract of Mentha sp. caused high inhibition of all CYP activities studied, which 
may be due to the presence of more non-polar compounds in that extraction type. Especially 
OH-MDZ reaction (CYP3A4) was inhibited, as illustrated in figure 15. 
Both water extract of Mentha sp. and Citrus grandis extract were found to have the lowest 
inhibitory effect on CYP3A4 (OH-MDZ) activity.   
 
 
Figure 15. The effects of plant extracts on CYP-catalyzed activities in human liver microsomes 
  
 
    
 
The IC50 values presented in table 15 were determined graphically based in figure 15, as 
already explained before. 
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Table 15. IC50 of plant extracts for CYP1A1/2, CYP2A6 and CYP3A4 activities in human microsomes. Values 
measured in μg.mL-1 
Plant extract CYP1A1/2 CYP2A6 CYP3A4 
Pinus sylvestris 179,65 489,92 >500 
Angelica archangelica 0,59 >500 134,318 
Mentha sp. (Ethanol extration) 34,14 365,48 341,802 
Mentha sp. (Water extration) 86,73 429,01 >500 





In this study, two structural classes of furocoumarins, angular and linear, were used. The 
angular furocoumarins used were: 5,6-dihydroxyangelicin, sphondin, lanatin, isobergapten 
and angelicin. The phytochemicals belonging to the linear class of furocoumarins used were: 
8-hydroxybergapten, phellopterin, cnidilin, bergaptol, isopimpinellin, bergamottin, 
imperatorin, psoralen, bergapten and xanthotoxin. 
5,6-Dihydroxyangelicin on basis of its IC50 values (presented in table 16) provokes a low 
inhibition (IC50 >10 μM) in in CYP3A4 (OH-MDZ). Sphondin was found to be a high 
inhibitor (IC50 < 1 μM) of CYP1A1/2 and CYP2A6, but a weak inhibitor of CYP3A4. 
However, it proved to be the strongest inhibitor of the angular furocoumarins present in this 
study. Lanatin was found to be only a strong inhibitor of CYP1A1/2. 
 
Table 16.  IC50 of angular furocoumarins for CYP1A1/2, CYP2A6 and CYP3A4 activities in human 
microsomes. Values measured in μM. 
Angular furocoumarins CYP1A1/2 CYP2A6 CYP3A4 
5,6-Dihydroxyangelicin 47,78 82,40 100,0 
Angelicin 0,694 3,940 >100,0 
Sphondin 0,824 0,850 64,76 
Isobergapten 3,628 27,69 >100,0 
Lanatin 0,720 >100,0 >100,0 
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The ECOD reaction (CYP1A1/2) is the most susceptible to inhibition when compared with 
other CYP-mediated reactions. It is inhibited by almost all angular and linear furocoumarins, 
expect for 5,6-dihydroxyangelicin and bergaptol (see table 16 and 17table 17). 
 
Table 17. IC50 of linear furocoumarins for CYP1A1/2, CYP2A6 and CYP3A4 activities in human microsomes.. 
Values measured in μM. 
Linear furocoumarins CYP1A1/2 CYP2A6 CYP3A4 
8-Hydroxybergapten 5,107 64,21 53,10 
Bergaptol 75,29 >100,0 >100,0 
Bergamottin 0,617 >100,0 52,97 
Bergapten 0,537 >100,0 >100,0 
Cnidillin 0,539 >100,0 >100,0 
Isopimpinellin 0,513 >100,0 64,84 
Imperatorin 0,539 77,55 2,537 
Phellopterin 0,487 >100,0 12,71 
Psoralen 0,591 >100,0 >100,0 
Xanthotoxin 0,5646 0,69 >100,0 
 
The most relevant inhibition by psoralen and angelicin were found toward CYP1A1/2 
(EROD). 
Bergaptol, bergapten and bergamottin inhibit mainly CYP3A4 in the intestine (Duke, 2008). 
In this study these compounds were found to be a weak inhibitor of hepatic CYP3A4 (OH-
MDZ). 
The stronger inhibitor among the linear furocoumarins of this study was imperatorin, 
followed by phellopterin with a moderate inhibition (IC50 between 1 and 10 μM). 
Isopimpinellin was found to be a strong inhibitor of CYP1A1/2. 
The only linear furocoumarins found in this study with a strong inhibition of CYP2A6 was 
xanthotoxin, which can be found in all parts of the plant Angelica archangelica (Duke, 2008). 
Isobergapten and cnidillin are present in several plants, especially in Angelica sp. The former 
was found to be a moderate inhibitor of CYP1A1/2 and the latter to be a strong inhibitor. 
8-hydroxybergapten is a characteristic compound found in Angelica dahurica. In this study it 








As part of this study pure α-thujone and mixed α-, β-thujone were tested as possible CYP 
inhibitors.  
In this study the two stereoisomeric forms of thujone showed weak inhibition of CYP 
activities studies (see table 18 and 19). Only, the IC50 value of coumarin 7-hydroxylase 
(CYP2A6) could be precisely determined. As illustrated in figure 16, both pure α-Thujone 
and α, β-Thujone mixture had the same inhibitory pattern. Nevertheless, α, β-Thujone mixture 
showed a lower IC50 of CYP2A6 (COH) than pure α-Thujone. 
 
Table 18. CYP-related activity in the presence of plant extracts 







Control  65,73 706,65 176,50 
1 61,10 672,37 140,00 
10 62,06 607,75 136,50 α-β-Thujone 
100 59,30 300,46 136,00 
1 57,87 673,90 150,00 
10 58,38 611,99 145,50 α-Thujone 
100 54,03 275,20 145,00 
1 pmol.min-1.mg-1; 2 μmol.min-1.mg-1 
 
 
Table 19. IC50 of thujone isomers for CYP1A1/2, CYP2A6 and CYP3A4 activities in human microsomes.. Values 
measured in μM. 
Compound CYP1A1/2 CYP2A6 CYP3A4 
α, β-Thujone >100 78,88 >100 
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The presented results, related to the comparison of CYP activities between different species, 
suggest the existence of significant inter-species differences in substrate models for individual 
CYP-catalyzed activities. Even with similar patterns for some CYP-catalyzed activities 
between species no link could be established to all group of CYP belonging to different 
species. For example, in ECOD reactions no possible relation was establish between species. 
It should be emphasized that all enzymatic model reactions studied are mainly targeted to 
human CYPs. However, similar probes but with slightly different experimental set-ups have 
been used to obtain animal CYP data in individual studies (Fink-Gremmels, 2008). 
In the present study, all enzymatic analyses were carried out as individual determinations 
using only two replicate incubations and not including the true variation within species, e.g. 
different levels of CYP expression depending on gender and race. 
Based on these data, to overtake some of these limitations, it should be used pools of hepatic 
microsomes divided at least in gender and age. 
The impossibility to perform extrapolations with all CYP-related activities of one species with 
another is one of the main consequences. Concerning animal models for human CYP-
mediated metabolism, it faces the same problem. In this case, it needs to be used different 
animal species depending on the human CYP selected. 
Concerning the variability of CYP activities and specificity verified between species, it is 
necessary more detailed studies, e.g. CYP genes sequencing for identification of CYPs 
involved in enzymatic activity and development of enzymatic model reactions targed to 
animal CYPs, because different species normaly catalyze the same reactions but by different 
CYPs and magnitude. 
Another aspect of this study was related with the identification of possible interferences of 
herbal compounds in CYP-related activities in human microsomes. The EROD reaction, 
performed by both CYP1A1 and CYP1A2, showed to be the most inhibited CYP-mediated 
reaction, especially by Angelica archangelica and most of the phytochemicals tested. Product 
of Angelica archangelica extraction was also the plant component with highest inhibition in 
CYP3A4 (OH-MDZ) activity. 
The COH reaction, catalyzed by CYP2A6, was inhibited by few compounds with low IC50 
values. The highest inhibition for this reaction was detected among the angular 
furocoumarins.  
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As already mentioned, CYP3A4 is one of the main responsible CYPs involved in drug 
metabolism. In this study, phytochemicals with lower inhibitory concentration were found in 
the linear furocoumarins group, especially by imperatorin. 
Based on the first study presented, owing to the similar activities found in some CYPs 
(e.g.CYP1A1/2) between the species analyzed, it may be possible to find comparable 
interferences with the same plant extracts and phytochemicals. In addition, the same kind of 
interferences is also expected to occur in other veterinary species, which include companion 
and farm animals. 
From all phytochemicals tested, thujone has been already identified as a major concern in 
veterinary medicine, owing to the ingestion of plants by wild or farm animals; and the use of 
ethanolic extraction of thuja as veterinary homeopathy treatment. In this study, the highest 
CYP inhibition of thujone in humans was found on CYP2A6, but the IC50 value represents a 
low inhibition (IC50 > 10 μM). Nevertheless, human CYP2A6 was found to have the highest 
COH activity (mouse CYP2A5 only possess 4%, minipig CYP2A has 23% and rabbit 
CYP2A10 has 65% of human CYP2A6 COH activity). The same applies to EROD reaction 
which has similar activities in the animals studied and for which most of furocoumarins and 
Angelica archangelica have a high inhibition. So, it may be possible to verify in these animals 
some inhibition by thujone and the other compounds at least in COH and EROD reactions, 
but more specific studies are needed. 
Taking in consideration all potential CYP inhibitions by plant extracts and phytochemicals 
tested, the information collected is still preliminary. Nevertheless, more detailed studies will 
be needed to understand the comparison of CYP-catalyzed activities between different 
species, the importance of these compounds in animal diets, and to know if these in vitro 
interactions have any real effect in vivo and consequently an impact in public health or 
medical care. For instances: 1) food-drug interactions can decrease metabolism delaying drug 
elimination, which represents a risk for public health in farm animals; 2) food-drug 
interactions can increase metabolism changing the eficacy of the treatment, which can lead to 
therapeutic failure or toxicity even with death of the pacient. 
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Comparison of in vitro activities of biotransformation enzymes in human, rabbit, 
minipig and mouse 
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Abstract 
Cytochrome P450 enzymes (CYP) are primarily membrane-associated proteins that belong to 
the superfamily of heme-thiolate enzymes. The main role attended by the CYP system in 
human and veterinary medicine is based mostly in the CYP mediated drug metabolism, which 
can result in either detoxification or metabolic activation, i.e. the formation of reactive forms 
from inactive parent compounds and it can lead to bioavailability problems, interindividual 
variation, metabolic interactions and idiosyncrasies. So, the absence of detailed information 
regarding biotransformation processes can result in adverse effects, therapeutic failure and 
toxicity from unanticipated overdose or metabolic reactions, such as drug-drug interactions 
(DDIs) and food-drug interactions (Fink-Gremmels, 2008; Nebbia, 2001; Olavi Pelkonen, 
2002). 
In contrast to the extensive data available for human and rodents, the characterization of the 
CYP system in other animal species is still incomplete. This is of importance in veterinary 
and human medicine, as many drugs are used in more than one species and also animal 
models can be used as experimental models of drug metabolism. Consequently, major 
obstacles are the significant inter-species and intra-species differences in substrate models for 
individual CYP-mediated reactions (Fink-Gremmels, 2008; Turpeinen, 2006; Zuber et al., 
2002). 
The present study compared hepatic drug metabolism characteristics of humans with three 
different laboratory animal species (rabbit, minipig and mouse), measuring CYP activities in 
vitro (MultiCYP 7-ethoxycoumarin 0-deethylase (ECOD), CYP1A1/2 7-ethoxyresorufin 0-
deethylase (EROD), CYP2A6 coumarin 7-hydroxylase, CYP3A4 midazolam 1-hydroxylase, 
and CYP2E1 chlorzoxazone 6-hydroxylase).  
The ECOD activity is catalyzed by several CYP450 forms in human liver microsomes, being 
used for general measure. The lowest activity is detected in humans and there is no similarity  
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between other species. The major human CYP family involved in EROD is CYP1A1/2, which 
may be different in other animal species (CYP2C?) (Turpeinen et al., 2007), shows equivalent 
activities. The highest CYP activities in humans, when compared with the other species, are 
found for CYP2A6 (e.g. 60x than mouse) and CYP3A4 (e.g. 15x than mouse). In CYP2E1 
activity, two similar groups can be recognized: human and mouse versus rabbit and minipig.  
 
